CN102816162A - 嘧啶并嘧啶酮类化合物及其药用组合物和应用 - Google Patents
嘧啶并嘧啶酮类化合物及其药用组合物和应用 Download PDFInfo
- Publication number
- CN102816162A CN102816162A CN2011101563999A CN201110156399A CN102816162A CN 102816162 A CN102816162 A CN 102816162A CN 2011101563999 A CN2011101563999 A CN 2011101563999A CN 201110156399 A CN201110156399 A CN 201110156399A CN 102816162 A CN102816162 A CN 102816162A
- Authority
- CN
- China
- Prior art keywords
- methyl
- pyrimidin
- phenyl
- dihydro
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 88
- -1 pyrimidone compound Chemical class 0.000 title claims description 88
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 79
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 75
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 74
- 239000001257 hydrogen Substances 0.000 claims description 74
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 150000003839 salts Chemical class 0.000 claims description 46
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 21
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 229960005181 morphine Drugs 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 11
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000005864 Sulphur Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 230000002596 correlated effect Effects 0.000 claims description 8
- XLJMAIOERFSOGZ-UHFFFAOYSA-N cyanic acid Chemical compound OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 8
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 8
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 150000003053 piperidines Chemical class 0.000 claims description 5
- 125000005936 piperidyl group Chemical group 0.000 claims description 5
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 150000003457 sulfones Chemical class 0.000 claims description 4
- 150000003462 sulfoxides Chemical class 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 208000019838 Blood disease Diseases 0.000 claims description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000005429 oxyalkyl group Chemical group 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 238000010572 single replacement reaction Methods 0.000 claims description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 34
- 229940079593 drug Drugs 0.000 abstract description 17
- 229940121647 egfr inhibitor Drugs 0.000 abstract description 10
- 230000035772 mutation Effects 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 9
- 210000004881 tumor cell Anatomy 0.000 abstract description 8
- 102000001301 EGF receptor Human genes 0.000 abstract description 4
- 108060006698 EGF receptor Proteins 0.000 abstract description 4
- 102000001253 Protein Kinase Human genes 0.000 abstract description 3
- 108060006633 protein kinase Proteins 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 38
- 238000000034 method Methods 0.000 description 37
- 239000002585 base Substances 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 31
- 230000008859 change Effects 0.000 description 27
- 102200048955 rs121434569 Human genes 0.000 description 24
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 24
- 239000002512 suppressor factor Substances 0.000 description 17
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 14
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 102000020233 phosphotransferase Human genes 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 12
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 229940120982 tarceva Drugs 0.000 description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 10
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 10
- 201000005296 lung carcinoma Diseases 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000002626 targeted therapy Methods 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 239000003513 alkali Substances 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000008261 resistance mechanism Effects 0.000 description 7
- 102200048928 rs121434568 Human genes 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 6
- 229950008835 neratinib Drugs 0.000 description 6
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 229940060038 chlorine Drugs 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 230000002427 irreversible effect Effects 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 229940074995 bromine Drugs 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229940121649 protein inhibitor Drugs 0.000 description 4
- 239000012268 protein inhibitor Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- HVXKQKFEHMGHSL-QKDCVEJESA-N tesevatinib Chemical compound N1=CN=C2C=C(OC[C@@H]3C[C@@H]4CN(C)C[C@@H]4C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1F HVXKQKFEHMGHSL-QKDCVEJESA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010029961 Filgrastim Proteins 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010066901 Treatment failure Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 3
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 229960003918 levothyroxine sodium Drugs 0.000 description 3
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 229960004622 raloxifene Drugs 0.000 description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- OGWKCGZFUXNPDA-CFWMRBGOSA-N 5j49q6b70f Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 OGWKCGZFUXNPDA-CFWMRBGOSA-N 0.000 description 2
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 2
- 101150039808 Egfr gene Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 229960001097 amifostine Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229960000510 ammonia Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 239000013038 irreversible inhibitor Substances 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- LYESCJLRRXBLPH-UHFFFAOYSA-N n-[3-[3-methyl-7-(methylamino)-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C12=NC(NC)=NC=C2CN(C)C(=O)N1C1=CC=CC(NC(=O)C=C)=C1 LYESCJLRRXBLPH-UHFFFAOYSA-N 0.000 description 2
- LBFKRSOXJCJXRZ-UHFFFAOYSA-N n-[3-[3-methyl-7-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C1CCN(C=2C=CC(NC=3N=C4N(C=5C=C(NC(=O)C=C)C=CC=5)C(=O)N(C)CC4=CN=3)=CC=2)CC1 LBFKRSOXJCJXRZ-UHFFFAOYSA-N 0.000 description 2
- VQXJJEGSNGGQJK-UHFFFAOYSA-N n-[3-[7-[2-methoxy-4-(4-methyl-1,4-diazepan-1-yl)anilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(C)CCC2)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 VQXJJEGSNGGQJK-UHFFFAOYSA-N 0.000 description 2
- ALLFOBCVMVMHJI-UHFFFAOYSA-N n-[3-[7-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 ALLFOBCVMVMHJI-UHFFFAOYSA-N 0.000 description 2
- NYAQSLDDXANMTL-UHFFFAOYSA-N n-[3-[7-[4-[4-(dimethylamino)piperidin-1-yl]anilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C1CC(N(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(CN(C)C(=O)N2C=3C=C(NC(=O)C=C)C=CC=3)C2=N1 NYAQSLDDXANMTL-UHFFFAOYSA-N 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 2
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 229960004249 sodium acetate Drugs 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229960002812 sunitinib malate Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- VESKBLGTHHPZJF-QNWVGRARSA-N (2s)-2-amino-5-[[(2r)-2-amino-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]propanoyl]-[(r)-carboxy(phenyl)methyl]amino]-5-oxopentanoic acid Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](N)C(=O)N(C(=O)CC[C@H](N)C(O)=O)[C@@H](C(O)=O)C1=CC=CC=C1 VESKBLGTHHPZJF-QNWVGRARSA-N 0.000 description 1
- ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- ZGMJYTYLTJFNCS-VQYXCCSOSA-N (e)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 ZGMJYTYLTJFNCS-VQYXCCSOSA-N 0.000 description 1
- 0 *Nc1nc(N(c2cc(N(*)*)ccc2)C(N(*)C2)=O)c2cn1 Chemical compound *Nc1nc(N(c2cc(N(*)*)ccc2)C(N(*)C2)=O)c2cn1 0.000 description 1
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical compound O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HQFWWONKNHWRHA-UHFFFAOYSA-N 1-(3-aminophenyl)-3-methyl-7-(methylamino)-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C12=NC(NC)=NC=C2CN(C)C(=O)N1C1=CC=CC(N)=C1 HQFWWONKNHWRHA-UHFFFAOYSA-N 0.000 description 1
- MDLKWDQMIZRIBY-UHFFFAOYSA-N 1-(dimethylamino)ethanol Chemical class CC(O)N(C)C MDLKWDQMIZRIBY-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- LGEXGKUJMFHVSY-UHFFFAOYSA-N 2-n,4-n,6-n-trimethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(NC)=NC(NC)=N1 LGEXGKUJMFHVSY-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- SDOFMBGMRVAJNF-UHFFFAOYSA-N 6-aminohexane-1,2,3,4,5-pentol Chemical compound NCC(O)C(O)C(O)C(O)CO SDOFMBGMRVAJNF-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZNQVKFSDGZWXTM-UHFFFAOYSA-N CC(C)(C)OC(Nc1cccc(N(c2c(CN3C)cnc(S(C)(=O)=O)n2)C3=O)c1)=O Chemical compound CC(C)(C)OC(Nc1cccc(N(c2c(CN3C)cnc(S(C)(=O)=O)n2)C3=O)c1)=O ZNQVKFSDGZWXTM-UHFFFAOYSA-N 0.000 description 1
- CLNKJBPZDGTMFG-HXUWFJFHSA-N CN[C@H](CC1)CN1c(cc1)cc(OC)c1Nc1ncc(CN(C)C(N2c3cccc(NC(C=C)=O)c3)=O)c2n1 Chemical compound CN[C@H](CC1)CN1c(cc1)cc(OC)c1Nc1ncc(CN(C)C(N2c3cccc(NC(C=C)=O)c3)=O)c2n1 CLNKJBPZDGTMFG-HXUWFJFHSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229940122964 Deacetylase inhibitor Drugs 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 102000040104 IAP family Human genes 0.000 description 1
- 108091069885 IAP family Proteins 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- BCZUAADEACICHN-UHFFFAOYSA-N SGX-523 Chemical compound C1=NN(C)C=C1C1=NN2C(SC=3C=C4C=CC=NC4=CC=3)=NN=C2C=C1 BCZUAADEACICHN-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241001279158 Silonia silondia Species 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 108700011582 TER 286 Proteins 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 229940123468 Transferase inhibitor Drugs 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- HPPONSCISKROOD-OYLNGHKZSA-N acetic acid;(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-y Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 HPPONSCISKROOD-OYLNGHKZSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 description 1
- 229950002421 acolbifene Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003235 allopurinol sodium Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 1
- UVJYAKBJSGRTHA-UHFFFAOYSA-N arglabin Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CCC32OC31C UVJYAKBJSGRTHA-UHFFFAOYSA-N 0.000 description 1
- 229950003620 asoprisnil Drugs 0.000 description 1
- GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 description 1
- 229960001862 atracurium Drugs 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical class CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229940041983 daunorubicin liposomal Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- LRCZQSDQZJBHAF-PUBGEWHCSA-N dha-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 229940063123 diflucan Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- 125000005058 dihydrotriazolyl group Chemical group N1(NNC=C1)* 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229950001287 edotecarin Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000010438 granite Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 1
- 229960005033 methyl aminolevulinate Drugs 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- JRIQEYXFGMOIRI-UHFFFAOYSA-N n-[3-(7-anilino-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl)phenyl]prop-2-enamide Chemical compound N1=C2N(C=3C=C(NC(=O)C=C)C=CC=3)C(=O)N(C)CC2=CN=C1NC1=CC=CC=C1 JRIQEYXFGMOIRI-UHFFFAOYSA-N 0.000 description 1
- AMFPVVQTYDTMMN-UHFFFAOYSA-N n-[3-[3-cyclopropyl-7-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C1N(C=2C=C(NC(=O)C=C)C=CC=2)C2=O)=NC=C1CN2C1CC1 AMFPVVQTYDTMMN-UHFFFAOYSA-N 0.000 description 1
- YWKIWDTZXNHPET-UHFFFAOYSA-N n-[3-[3-methyl-2-oxo-7-(4-piperidin-1-ylanilino)-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound N1=C2N(C=3C=C(NC(=O)C=C)C=CC=3)C(=O)N(C)CC2=CN=C1NC(C=C1)=CC=C1N1CCCCC1 YWKIWDTZXNHPET-UHFFFAOYSA-N 0.000 description 1
- HKKAPBXZQFYMGT-UHFFFAOYSA-N n-[3-[3-methyl-2-oxo-7-(4-thiomorpholin-4-ylanilino)-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound N1=C2N(C=3C=C(NC(=O)C=C)C=CC=3)C(=O)N(C)CC2=CN=C1NC(C=C1)=CC=C1N1CCSCC1 HKKAPBXZQFYMGT-UHFFFAOYSA-N 0.000 description 1
- YDRKIZXMZYJDGY-UHFFFAOYSA-N n-[3-[3-methyl-7-(4-methylpiperazin-1-yl)-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C1=NC=C(CN(C)C(=O)N2C=3C=C(NC(=O)C=C)C=CC=3)C2=N1 YDRKIZXMZYJDGY-UHFFFAOYSA-N 0.000 description 1
- LOCISIRDSVBKGH-UHFFFAOYSA-N n-[3-[3-methyl-7-(4-morpholin-4-ylanilino)-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound N1=C2N(C=3C=C(NC(=O)C=C)C=CC=3)C(=O)N(C)CC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 LOCISIRDSVBKGH-UHFFFAOYSA-N 0.000 description 1
- ZZGGOXMEIWLVTJ-UHFFFAOYSA-N n-[3-[3-methyl-7-[2-methyl-4-(4-methylpiperazin-1-yl)anilino]-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1C)=CC=C1NC1=NC=C(CN(C)C(=O)N2C=3C=C(NC(=O)C=C)C=CC=3)C2=N1 ZZGGOXMEIWLVTJ-UHFFFAOYSA-N 0.000 description 1
- FDEKMPDQEHGRKB-UHFFFAOYSA-N n-[3-[3-methyl-7-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound CC(C)OC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 FDEKMPDQEHGRKB-UHFFFAOYSA-N 0.000 description 1
- LMGUBGLYTIBZRC-UHFFFAOYSA-N n-[3-[3-methyl-7-[4-(4-methylpiperazin-1-yl)anilino]-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(CN(C)C(=O)N2C=3C=C(NC(=O)C=C)C=CC=3)C2=N1 LMGUBGLYTIBZRC-UHFFFAOYSA-N 0.000 description 1
- MYGPUCMHVBVSTH-UHFFFAOYSA-N n-[3-[7-(2-methoxy-4-morpholin-4-ylanilino)-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 MYGPUCMHVBVSTH-UHFFFAOYSA-N 0.000 description 1
- LVNSLWQSIRXKLZ-UHFFFAOYSA-N n-[3-[7-(2-methoxy-4-piperidin-1-ylanilino)-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCCCC2)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 LVNSLWQSIRXKLZ-UHFFFAOYSA-N 0.000 description 1
- LCLGYKIVJKDWOH-UHFFFAOYSA-N n-[3-[7-(2-methoxy-4-pyrrolidin-1-ylanilino)-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCCC2)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 LCLGYKIVJKDWOH-UHFFFAOYSA-N 0.000 description 1
- GCGGRVMBZDBXQU-UHFFFAOYSA-N n-[3-[7-(2-methoxy-4-thiomorpholin-4-ylanilino)-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCSCC2)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 GCGGRVMBZDBXQU-UHFFFAOYSA-N 0.000 description 1
- UCJOIOBLGZJVCC-UHFFFAOYSA-N n-[3-[7-[2-ethoxy-4-(4-methylpiperazin-1-yl)anilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound CCOC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 UCJOIOBLGZJVCC-UHFFFAOYSA-N 0.000 description 1
- NTELLZOPFKQQHJ-UHFFFAOYSA-N n-[3-[7-[2-fluoro-4-(4-methylpiperazin-1-yl)anilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1F)=CC=C1NC1=NC=C(CN(C)C(=O)N2C=3C=C(NC(=O)C=C)C=CC=3)C2=N1 NTELLZOPFKQQHJ-UHFFFAOYSA-N 0.000 description 1
- AURZNILBUBQWGR-UHFFFAOYSA-N n-[3-[7-[2-methoxy-4-(2-methoxyethoxy)anilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(OCCOC)=CC=C1NC1=NC=C(CN(C)C(=O)N2C=3C=C(NC(=O)C=C)C=CC=3)C2=N1 AURZNILBUBQWGR-UHFFFAOYSA-N 0.000 description 1
- SSCRJLIJSQWPIB-UHFFFAOYSA-N n-[3-[7-[2-methoxy-4-(2-morpholin-4-ylethoxy)anilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C=1C=C(NC=2N=C3N(C=4C=C(NC(=O)C=C)C=CC=4)C(=O)N(C)CC3=CN=2)C(OC)=CC=1OCCN1CCOCC1 SSCRJLIJSQWPIB-UHFFFAOYSA-N 0.000 description 1
- RXRZLNAQLIRKLZ-UHFFFAOYSA-N n-[3-[7-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-2-oxo-3-propan-2-yl-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1CN(C(C)C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 RXRZLNAQLIRKLZ-UHFFFAOYSA-N 0.000 description 1
- WCMZSHAXEROLME-UHFFFAOYSA-N n-[3-[7-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-3-(4-methoxyphenyl)-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C1=CC(OC)=CC=C1N1C(=O)N(C=2C=C(NC(=O)C=C)C=CC=2)C2=NC(NC=3C(=CC(=CC=3)N3CCN(C)CC3)OC)=NC=C2C1 WCMZSHAXEROLME-UHFFFAOYSA-N 0.000 description 1
- YGTKHRLJFNTWPC-UHFFFAOYSA-N n-[3-[7-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 YGTKHRLJFNTWPC-UHFFFAOYSA-N 0.000 description 1
- NOVRNVMLNCWCAO-UHFFFAOYSA-N n-[3-[7-[3-methoxy-4-(4-methylpiperazin-1-yl)anilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound C=1C=C(N2CCN(C)CC2)C(OC)=CC=1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 NOVRNVMLNCWCAO-UHFFFAOYSA-N 0.000 description 1
- UYSIOHMFCNZCRU-UHFFFAOYSA-N n-[3-[7-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 UYSIOHMFCNZCRU-UHFFFAOYSA-N 0.000 description 1
- JKYJOELEQGFEIS-UHFFFAOYSA-N n-[3-[7-[4-(dimethylamino)-2-methoxyanilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N(C)C)=CC=C1NC1=NC=C(CN(C)C(=O)N2C=3C=C(NC(=O)C=C)C=CC=3)C2=N1 JKYJOELEQGFEIS-UHFFFAOYSA-N 0.000 description 1
- GSJLURAJKVXEOS-HSZRJFAPSA-N n-[3-[7-[4-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2C[C@@H](CC2)N(C)C)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 GSJLURAJKVXEOS-HSZRJFAPSA-N 0.000 description 1
- GSJLURAJKVXEOS-QHCPKHFHSA-N n-[3-[7-[4-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2C[C@H](CC2)N(C)C)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 GSJLURAJKVXEOS-QHCPKHFHSA-N 0.000 description 1
- QBBSBGDJPPSSKJ-UHFFFAOYSA-N n-[3-[7-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyanilino]-3-methyl-2-oxo-4h-pyrimido[4,5-d]pyrimidin-1-yl]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCC(CC2)N(C)C)=CC=C1NC(N=C12)=NC=C1CN(C)C(=O)N2C1=CC=CC(NC(=O)C=C)=C1 QBBSBGDJPPSSKJ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 description 1
- 229960003359 palonosetron hydrochloride Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229940073479 prednisolone oral solution Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- NPSSWQJHYLDCNV-UHFFFAOYSA-N prop-2-enoic acid;hydrochloride Chemical compound Cl.OC(=O)C=C NPSSWQJHYLDCNV-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- PTJRZVJXXNYNLN-UHFFFAOYSA-M sodium;2h-pyrazolo[3,4-d]pyrimidin-1-id-4-one Chemical compound [Na+].[O-]C1=NC=NC2=C1C=NN2 PTJRZVJXXNYNLN-UHFFFAOYSA-M 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- XASYUPMTFSQQEV-UHFFFAOYSA-N tert-butyl n-[3-[[5-(hydroxymethyl)-2-methylsulfanylpyrimidin-4-yl]amino]phenyl]carbamate Chemical compound CSC1=NC=C(CO)C(NC=2C=C(NC(=O)OC(C)(C)C)C=CC=2)=N1 XASYUPMTFSQQEV-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950005976 tivantinib Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229960000434 triptorelin acetate Drugs 0.000 description 1
- 229960000294 triptorelin pamoate Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- KIGCDEJCMKDBHU-NIQQUOCOSA-K ukrain Chemical compound [OH-].[OH-].[OH-].C([C@H](O)[C@@H]1C2=CC=C3OCOC3=C2C2)C3=CC=4OCOC=4C=C3[C@H]1[N+]2(C)CCNP(=S)(NCC[N+]1(C)[C@@H]2C3=CC=4OCOC=4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1)NCC[N+]1(C)[C@@H]2C3=CC(OCO4)=C4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1 KIGCDEJCMKDBHU-NIQQUOCOSA-K 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 108700029852 vapreotide Proteins 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229940072018 zofran Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了由通式(I)或(II)表示7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物及其在制备治疗肿瘤药物中的应用。经研究证实,它们能过抑制多种肿瘤细胞增殖,可用于靶向抑制表皮生长因子受体激酶(EGFR),尤其有效抑制EGFR(T790M)突变株的单点突变或多点突变癌细胞。因此可作为EGFR抑制剂用于抗癌药物的使用,有较大的应用价值。
Description
技术领域
本发明属于化学医药领域,具体地涉及具有一类嘧啶并嘧啶酮类化合物或其药学上可接受的盐或立体异构体及其前药分子,含有这种化合物的药物组合物和这些化合物或组合物在制备药物中的应用。
发明背景
无论在世界范围内还是在中国,以恶性肿瘤(癌症)、心血管疾病以及糖尿病等为代表的慢性病(或者说非传染性疾病),却正在成为更主要的长期威胁。2008年5月19日,世界卫生组织在其最新公布的报告中就明确指出,非传染性疾病正在成为人类最为致命的“杀手”。其中,癌症位列首位。2004年,全球有740万人死于癌症,其中,中国的情况则更为严峻。2008年4月底公布的第三次全国死因回顾调查表明,中国城乡居民的癌症死亡率在过去30年中增长了八成以上;其中每四到五个死亡的中国人中就有一个人死于癌症。中国每年死于癌症的总人口,接近200万人。近年来,各种各样的治疗途径以及药物的发现虽对癌症患者带来的希望,但是常规治疗的弊端,副作用大,治疗效果不佳,肿瘤预后复发,转移等现象迫切需要新的治疗技术来解决这类瓶颈作用。国际医学界将分子分型基础上的个体化化疗和靶向治疗看作是突破目前肺癌治疗瓶颈的希望所在。
肿瘤分子靶向治疗是基于对肿瘤生长密切相关的关键分子通过化学或生物学手段选择性杀伤肿瘤细胞的一种治疗方法。靶向治疗的特点为:特异性高,选择性强,毒副作用较轻;联合应用时,它可加强传统化疗、放疗的疗效,减少术后复发。以伊马替尼甲磺酸盐(STI571)(Novartis,2001),吉非替尼(ZD1839)(AstraZeneca,2003),厄罗替尼(OSI774)(Genentechand OSIP,2004),索拉菲尼对甲苯磺酸盐(Bay 43-9006)(Bayer and Onyx,2005),舒尼替尼苹果酸盐(SU11248)(Pfizer,2006)以及达沙替尼(BMS-354825)(Bristol-Myers Squibb,2006)为代表的靶向药物为肿瘤化疗开创了一个新时代。肿瘤靶向治疗在短短几年内得到了迅速发展。肿瘤靶向治疗的出现已对传统给药观念和模式构成冲击,例如,因毒副作用小靶向药物在I期临床试验中往往无法达到剂量限制性毒性和最大耐受剂量;用靶向治疗药物时无需用最大耐受剂量即可达到满意疗效。肿瘤靶向治疗是肿瘤治疗的热点和发展趋势。
蛋白酪氨酸激酶(PTKs)是一类能够催化多种重要蛋白质的酪氨酸残基上的酚羟基发生磷酸化,进而激活功能蛋白的功能的蛋白质酶系。人体内的520多种蛋白激酶中大约有一半是酪氨酸激酶(PTKs)。它们在细胞内的信号传导通路中占据了十分重要的地位,调节着细胞体内生长、分化、死亡等一系列生理化过程。蛋白酪氨酸激酶功能失调会引发生物体内的一系列疾病。研究表明,半数以上的原癌基因和癌基因的激活都与蛋白酪氨酸激酶相关。蛋白酪氨酸激酶的异常表达可导致细胞增殖调节发生紊乱,进而导致肿瘤发生。此外,酪氨酸激酶的异常表达还与肿瘤的侵袭和转移,肿瘤新生血管的生成,肿瘤的化疗抗药性密切相关。以酪氨酸激酶为靶点进行抗肿瘤药物研发成为国际上的一个热点,也是各国药物开发机构研究投入的重点。
表皮生长因子受体(EGFR),一种受体酪氨酸蛋白激酶,调控了细胞的增值,存活,粘连,迁移与分化。EGFR在多种肿瘤细胞中过度活化或持续活化,比如肺癌,乳腺癌,前列腺癌等。EGFR是一种跨膜蛋白,其家族有四种亚型:EGFR-1(后来被称为EGFR,Erb-B1或Her-1),HER-2(Erb-B2,或neu),HER-3(Erb-B3),和HER-4(Erb-B4)。其中EGFR和Erb-B2的异常活化在肿瘤的转化与增长中起着关键性的作用。阻断EGFR和Erb-B2的活化已被临床验证为主导的方法来靶向治疗肿瘤细胞。以肺癌为例,EGFR在50%的NSCLC病例中有表达,而且其表达与预后不佳相关。这两个因素使得EGFR及其家族成员成为开展靶向治疗的主要候选者。两种靶向EGFR的小分子抑制剂,吉非替尼和厄洛替尼,得到了美国FDA的快速批准用于治疗晚期NSCLC患者,这些患者对常规化疗已经失去了反应。
早期的临床数据表明,10%的NSCLC患者对吉非替尼和厄洛替尼有反应。这种显著的临床疗效可见于特定的患者群体,包括非吸烟的东亚地区女性和表现为支气管肺泡性病理类型的腺癌患者。分子水平的分析表明,在多数情况下,对药物有反应的患者在编码EGFR基因上带有特定的突变。第19外显子的第747~750位氨基酸的缺失占突变的45%,还有10%的突变在第18和第20外显子。EGFR激酶结构域的突变高度激活激酶,使得肿瘤细胞的生存对突变激酶具有依赖性。已有多项前瞻性临床研究证实,EGFR活化突变阳性的NSCLC患者对EGFR-TKI的反应率显著高于EGFR野生型NSCLC患者,无进展生存(PFS)期和总生存(OS)期也显著延长。但尽管如此,大部分EGFR突变阳性患者的PFS不超过12~14个月,即对TKI发生了耐药。获得性耐药的机制及其临床应对策略成为靶向治疗领域的又一研究热点。
靶向EGFR抑制剂耐药机制可分为两类:耐药突变和旁路激活途径。耐药机制1:T790M突变是EGFR 20外显子中的一个点突变,是目前较为认可的耐药机制之一。T790M导致TKI耐药的机制尚不完全清楚。最初的研究显示,T790M可能改变了激酶区腺苷三磷酸(ATP)结合口袋的晶体结构,封闭了TKI与激酶区的结合。最新研究显示,L858R合并T790M突变对ATP的亲和力比单纯L858R强,而TKI是ATP竞争性激酶抑制剂,故导致TKI与激酶区结合率降低。关于T790M的争议之一是,该突变是在TKI治疗后产生还是原本就存在、经TKI治疗选择后才被发现。最初,T790M只在TKI治疗失败的NSCLC患者标本中被发现,但随后在未经任何治疗的标本中也被发现,故目前认为,该突变也存在于未经TKI治疗的肿瘤组织中,但仅见于少数细胞克隆,由于这些细胞克隆对TKI的抵抗性而在治疗后被选择出来。与T790M相似的耐药突变还有D761Y、L747S和T854A等,这些突变统称为“非T790M继发突变”,其总发生率低于5%。耐药机制2:MET扩增是2007年发现的又一EGFR-TKI获得性耐药机制。MET是一种跨膜酪氨酸激酶受体。在对TKI获得性耐药的EGFR突变阳性NSCLC患者中,约20%有野生型MET基因扩增,且大部分在治疗前无MET扩增。MET联合ErbB家族成员,绕过EGFR活化下游AKT介导的信号通路,促进肿瘤细胞生长,抑制其凋亡。在体外实验中,通过RNA干扰技术抑制MET信号通路,可恢复耐药者对吉非替尼的敏感性。同时抑制EGFR和MET,可克服MET扩增介导的TKI耐药。其他还有些受体与MET作用类似。最近的体外TKI耐药模型显示,胰岛素样生长因子1受体(IGF-1R)也可绕过EGFR,激活其下游信号通路,但由于技术原因,很难在患者标本中进行IGF-1R活化检测。这些绕过EGFR、激活其下游信号通路的耐药机制统称为“旁路激活途径”。对TKI耐药的EGFR突变阳性患者,约30%~40%既无继发突变,也无MET扩增,这些患者的耐药机制还在探索中。
针对耐药性,临床上采用的策略是:策略1,继续使用EGFR-TKI,吉非替尼和厄洛替尼的交叉使用。总之,TKI进展后继续使用TKI似有一定益处,但获益程度非常有限。策略2,开发新型EGFR-TKI。临床前研究显示,EGFR不可逆抑制剂可在体外抑制T790M,此后,很多EGFR不可逆抑制剂被研制出来,称为“二代EGFR-TKI”,目前已从临床前研究逐渐走向临床,研究较多的有neratinib、XL647、BIBW 2992和PF-00299804。Neratinib是泛ErbB(EGFR、ErbB2和ErbB3)不可逆TKI。基于I期研究结果,目前正在开展临床研究,探讨在吉非替尼或厄洛替尼治疗后进展的NSCLC患者中,neratinib(240mg/d)是否能克服T790M突变或MET扩增导致的TKI耐药。但一些临床前研究显示了不利结果,一种EGFR 19外显子缺失的细胞株PC-9在暴露于neratinib时,产生了T790M突变;在鼠L858R-T790M肿瘤模型中,单用neratinib未使肿瘤缓解。故neratinib对T790M突变者是否有效尚不得知。XL647能不可逆抑制EGFR、HER2、血管内皮生长因子受体2(VEGFR-2)和EphB4,在L858R-T790M突变模型中,可抑制肿瘤生长。2008年,一项关于XL647的II期临床研究初步显示,在34例吉非替尼或厄洛替尼治疗缓解超过3个月后发生疾病进展或伴有T790M突变的NSCLC患者中,用XL647(300mg/d)治疗后,仅1例部分缓解,该患者不吸烟,19外显子缺失,血浆中无T790M突变;而T790M突变阳性的患者无一缓解,大部分在2个月内进展。BIBW 2992是EGFR和ErbB2的不可逆TKI。在II期临床研究中,BIBW 2992使有19外显子缺失,L858R、L861Q及G719S/S768I突变患者出现缓解。一项BIBW 2992三线治疗化疗失败、吉非替尼或厄洛替尼获益后进展NSCLC的临床研究正在开展。BIBW 2992对比安慰剂,三线治疗吉非替尼或厄洛替尼治疗失败NSCLC的随机IIb/III期临床研究也在进行中。这些研究将有助于确定BIBW 2992能否给吉非替尼或厄洛替尼耐药患者带来益处。PF-00299804是泛ErbB TKI抑制剂。在I期临床研究中,1例T790M突变阳性者出现疾病缓解。PF-00299804(45mg/d)治疗KRAS野生型、化疗和厄洛替尼治疗失败NSCLC患者的II期临床研究正在开展。策略3,针对其他靶点治疗。由于“旁路激活途径”在EGFR-TKI耐药中发挥重要作用,针对这些旁路的靶向药物不断涌现。MET-TKI可能在伴有MET扩增的患者中发挥作用。临床前研究显示,EGFR-TKI与MET-TKI联合,对EGFR突变阳性且伴有MET扩增的细胞株有效,但两者单独使用均无效。一个重要的问题是,约一半具有MET扩增的患者同时具有T790M突变,故MET-TKI可能需要与T790M抑制剂联合。XL184是一种新型TKI,对MET、VEGFR-2和RET有抑制作用。其他MET抑制剂,如ARQ197、PF-2341066、SGX523等,也有相关临床研究在进行。PF-2341066是一种选择性c-MET和ALK受体酪氨酸激酶抑制剂,在I期临床研究中展示了较好的肿瘤控制效果,尤其是对ALK-EML4融合基因阳性患者。关于PF-2341066的II/III期临床研究正在开展,其已然成为靶向治疗领域的一个新热点。针对其他可能的旁路激活途径,一些药物,如IGF-1R抑制剂、热休克蛋白90抑制剂等的相关研究也在进行之中。
总之,目前的EGFR-TKI仍不能解决药物耐药性所引起的临床压力,而且现有的药物多是以喹唑啉或者喹啉胺类为基本母核的EGFR可逆或不可逆抑制剂,其对野生型细胞的选择性差带来的毒副作用也是不可避免的。因此,迫切需要新类型的,尤其是新颖骨架的化合物来解决耐药性,选择性差等问题。
发明内容
本发明需要解决的技术问题之一是提供一种新的嘧啶并嘧啶酮类化合物。
解决上述技术问题的技术方案如下:
具有式(I)或(II)结构的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物或者其药学上可接受的盐或立体异构体或其前药分子:
Y任选自:CH或N。
R1任选自:
1).H;
2).C1~C5烷基;
3).C3~C6环烷基;
4).C1~C5含氟烷基;
卤素,氰基,硝基,羟基,氨基,C1~C6烷基,C3~C6环烷基,C1~C6含氟烷基,C1~C6含杂原子烷基,C1~C7杂环基以及上述烷基形成的酯,酰胺,砜,亚砜,脲等;
R2任选自:
1).H;
2).C1~C5烷基;
3).C3~C6环烷基;
4).C1~C5含氟烷基;
5).芳基;
6).杂环基;
R3任选自:
1).H;
2).卤素;
3).氨基,羟基,氰基,硝基;
4).C1~C5烷基;
5).C3~C6环烷基;
6).芳基;
W任选自:CH2,CH2CH2,O,S,NH,NR;R为烷基,芳基;
R4任选自:
1)H;
2)卤素;
3)C1~C5烷基;
4)C3~C6环烷基
5)芳基;
以上所述环烷基、芳基可任选被0,1,2或3个任选自R5的取代基取代;
R5任选自:
1)H;
2)卤素;
3)C1~C3烷基;
4)C3~C6环烷基;
5)C1~C3烷氧基;
6)C1~C3含氟烷基;
7)杂环基;
8)C0~C3亚烷基-杂环基;
9)苯基。
优选地,所述的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物或者其药学上可接受的盐,其具有式III结构:
R3如上所述;
所述R1优先选自:
1)H;
2)甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;正戊基,异戊基,新戊基;
3)环丙基,环丁基,环戊基,环己基;
4)(CH2)nX,n=0~6,X为羟基,氨基,甲氧基,乙氧基,甲氧基乙氧基,乙氧基乙氧基相关含氧烷基,甲巯基,N,N-二甲基,N-甲基哌嗪基,吗啡啉基,硫啡啉基,哌啶基,四氢吡咯基,4-N,N-二甲基哌啶基,1-甲基-4-(哌嗪-4-取代)哌啶基,咪唑基,6-(4-甲基哌嗪-1-取代)-3-取代吡啶基相关杂环;
A1,A2,A3,A4,A5任选自:H,氟,氯,溴,碘,甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;正戊基,异戊基,新戊基相关支链烷烃,甲氧基,乙氧基,异丙氧基,叔丁氧基,甲氧基乙氧基,乙氧基乙氧基相关含氧烷烃,三氟甲基相关含氟烷烃,N,N-二甲基氨基乙氧基,N,N-二甲基氨基丙氧基,2-(N-甲基哌嗪基)乙氧基,2-(N-乙酰基哌嗪基)乙氧基,2-吗啡啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,2-四氢吡咯基乙氧基相关杂环烷氧基,N-甲基哌嗪基,吗啡啉基,硫啡啉,哌啶,四氢吡咯,咪唑,3-N,N-二甲基四氢吡咯,4-N,N-二甲基哌啶,4-乙酰基哌嗪,1-甲基-4-(哌嗪-4-取代)哌啶,4-(4-甲基哌嗪-1-取代)甲基,1-甲基哌啶-4-氨基,4-哌嗪-2-酮,1-甲基-4-哌嗪-2-酮相关杂环,以及上述基团形成的酯,酰胺,砜,亚砜,脲;
所述R2优先选自:
1)H;
2)甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;正戊基,异戊基,新戊基;
3)环丙基,环丁基,环戊基,环己基;
4)苯基,苄基,对甲氧基苯基,联苯基,4-苯氧基苯基,4-苄氧基苯基,2,4二氯苯基,3-氯-4-氟苯基单取代或多取代苯基,1-奈基,2-萘基。
优选地,所述的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物或者其药学上可接受的盐,其具有式IV结构:
R1、R2如上所述;
所述R6,R7任选自:
1)H;
2)甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;正戊基,异戊基,新戊基;
3)环丙基,环丁基,环戊基,环己基;
4)苯基;
W任选自:CH2,CH2CH2,O,S,NH,NR;R为甲基,乙基,苯基;
R4优先选自:
1)H;
2)氟,氯,溴,碘;
3)甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;
4)环丙基,环丁基,环戊基,环己基;
5)苯基,单取代或多取代苯基,稠环以及含杂原子稠环。
本发明另一目的是提供一种治疗肿瘤的药用组合物。
实现上述目的的技术方案如下:
一种治疗肿瘤的药用组合物,其药学活性成份为上述的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物或其药学上可接受的盐或立体异构体或其前药分子。
本发明另一目的是提供一种上述化合物的应用。
具体技术方案如下:
所述7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物及其药学上可接受的盐或立体异构体或其前药分子在制备治疗肿瘤的药物中的应用。
所述肿瘤为非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、胰腺癌、乳腺癌、前列腺癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌、鼻咽癌中的任一种。
本发明涉及具有通式(I)(II)结构特征的嘧啶并嘧啶酮类化合物,可以抑制多种肿瘤细胞,尤其是能够选择性作用于EGFR L858R/T790M以及EGFR E745_A750/T790M肺癌细胞。对比野生型癌细胞,该类化合物的IC50要高10倍,100倍甚至1000倍的数量级差别。该类化合物是一类新颖的能够克服现有EGFR-TKI耐药的并具有选择性的蛋白激酶抑制剂。
本发明涉及的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物及其药学上可接受的盐,可以有效抑制多种肿瘤细胞的生长,并对EGFR,Her家族其他蛋白酶产生抑制作用,可用于制备抗肿瘤药物,并可以克服现有药物吉非替尼,厄洛替尼等诱发的耐药。如本领域技术人员所理解的,本申请所涉及的化合物及其药学可接受的盐可用于制备治疗人类及其它哺乳动物的肿瘤等过渡增殖性疾病。
附图说明
附图1-11为EGFR-WT激酶EC50测试结果;
附图12-22为EGFR-T790M激酶EC50测试结果;
附图23,24,25,26为化合物对肺癌细胞的MTT实验结果;
附图27,28为化合物C-EGF06对肺癌细胞周期的影响;
附图29为化合物C-EGF06对肺癌细胞凋亡的影响;
附图30为化合物C-EGF06对肺癌细胞信号通路的影响。
具体实施方式
本发明所述化学物中,当任何变量(例如R1、R等)在任何组分中出现超过一次,则其每次出现的定义独立于其它每次出现的定义。同样,允许取代基及变量的组合,只要这种组合使化合物稳定。自取代基划入环系统的线表示所指的键可连接到任何能取代的环原子上。如果环系统为.多环,其意味着这种键仅连接到邻近环的任何适当的碳原子上.要理解本领域普通技术人员可选择本发明化合物的取代基及取代型式而提供化学上稳定的并可通过本领域技术和下列提出的方法自可容易获得的原料容易的合成的化合物。如果取代基自身被超过一个基团取代,应理解这些基团可在相同碳原子上或不同碳原子上,只要使结构稳定.短语“任选被一个或多个取代基取代”被认为与短语“任选被至少一个取代基取代”相当且在此情况下优选的实施方案将具有0-3个取代基。
本文所用术语“烷基”和“亚烷基”意指包括具有特定碳原子数目的支链的和直链的饱和脂肪烃基。例如,“C1-C5烷基“中”C1-C5“的定义包括以直链或支链排列的具有1、2、3、4、或5个碳原子的基团。例如,”C1-C5烷基“具体包括甲基、乙基、正丙基、异丙基、正丁基、叔丁基、异丁基、戊基。术语“环烷基”指具有特定碳原子数目的单环饱和脂肪烃基。例如“环烷基”包括环丙基、甲基-环丙基、2,2-二甲基-环丁基、2-乙基-环戊基、环己基等。
本文所用术语“杂芳基”代表环中多达6个原子的稳定的单环或每个环中多达6个原子双环碳环,其中至少一个环为芳香环且含有1-4个选自O、N和S的杂原子。本定义范围内的杂芳基包括但不限于:咪唑基、三唑基、吡唑基、呋喃基、噻吩基、噁唑基、异噁唑基、吡嗪基、哒嗪基、吡啶基、嘧啶基、吡咯基。对于下列杂芳基的定义,“杂芳基”也理解为包括任何含有氮的杂芳基的N-氧化物衍生物。在杂芳基取代基是双环的且含有一个环为非芳香性或不含有杂原子的例子中,应理解各自经芳香环或经含杂原子环连接。
本文中所用术语“杂环”或“杂环基”是指含有1-4个选自O、N和S的杂原子的5元-6元芳香性或非芳香性杂环,且包括双环基团。“杂环基”因此包括上面提及的杂芳基,也包括其二氢化及四氢化类似物。“杂环基”进一步的实施例包括但不限于:咪唑基、吲哚基、异噻唑基、异噁唑基、噁二唑基、噁唑基、氧杂环丁烷基(oxetanyl)、吡喃基、吡嗪基、吡唑基、哒嗪基、吡啶基、嘧啶基、吡咯基、喹噁啉基、四唑基、噻二唑基、噻唑基、噻吩基、三唑基、1,4-二噁烷基、吡咯烷基、二氢咪唑基、二氢异噁唑基、二氢异噻唑基、二氢噁二唑基、二氢噁唑基、二氢吡嗪基、二氢吡唑基、二氢吡啶基、二氢嘧啶基、二氢吡咯基、二氢四唑基、二氢噻二唑基、二氢噻唑基、二氢噻吩基、二氢三唑基、二氢氮杂环丁烷基、四氢呋喃基和四氢噻吩基,及其N-氧化物。杂环取代基的连接可通过碳原子或通过杂原子实现.在一个实施方案中,杂环选自咪唑基、吡啶基、1-吡咯烷酮、2-哌啶酮、2-嘧啶酮、2-吡咯烷酮、噻吩基、噁唑基、三氮唑基、异噁唑基。
正如本领域技术人员所理解的,本文中所用“卤素”(“halo”)或“卤素”意指包括氯、氟、溴和碘。
除非另有定义,烷基、环烷基、芳基、杂芳基和杂环基取代基可为未被取代的或取代的。例如,(C1-C6)烷基可被一个、两个或三个选自OH、卤素、烷氧基、二烷基氨基或杂环基例如吗啉基、哌啶基等的取代基取代。
在某些例子中,定义Het使其可与连接它们的氮共同形成4-7元单环或每个环为4-7元的双环杂环,且任选含有除氮外一个或两个选自N、O和S的另外的杂原子,所述杂环任选被一个或多个选自R2的取代基取代。可如此形成的杂环的实施例包括但不限于下列的杂环,须牢记杂环任选被一个或多个(且优选一个、两个或三个)选自R2的取代基取代:
本发明包括式I-IV化合物的游离形式,也包括其药学上可接受的盐及立体异构体。本文中一些特定的示例性化合物为胺类化合物的质子化了的盐。术语“游离形式”指以非盐形式的胺类化合物。包括在内的药学上可接受盐不仅包括本文所述特定化合物的示例性盐,也包括所有式I-IV化合物游离形式的典型的药学上可接受的盐。可使用本领域已知技术分离所述化合物特定盐的游离形式。例如,可通过用适当的碱稀水溶液例如NaOH稀水溶液、碳酸钾稀水溶液、稀氨水及碳酸氢钠稀水溶液处理该盐使游离形式再生。游离形式在某些物理性质例如在极性溶剂中溶解度上与其各自盐形式多少有些区别,但是为发明的目的这种酸盐及碱盐在其它药学方面与其各自游离形式相当。
可通过常规化学方法自含有碱性部分或酸性部分的本发明化合物合成本发明的药学上可接受的盐。通常,通过离子交换色谱或通过游离碱和化学计算量或过量的所需盐形式的无机或有机酸在适当溶剂或多种溶剂的组合中反应制备碱性化合物的盐。类似的,通过和适当的无机或有机碱反应形成酸性化合物的盐。
因此,本发明化合物的药学上可接受的盐包括通过碱性本发明化合物和无机或有机酸反应形成的本发明化合物的常规无毒盐。例如,常规的无毒盐包括得自无机酸例如盐酸、氢溴酸、硫酸、氨基磺酸、磷酸、硝酸等的盐,也包括自有机酸例如乙酸、丙酸、琥珀酸、乙醇酸、硬脂酸、乳酸、苹果酸、酒石酸、柠檬酸、抗坏血酸、扑酸、马来酸、羟基马来酸、苯乙酸、谷氨酸、苯甲酸、水杨酸、对氨基苯磺酸、2一乙酰氧基一苯甲酸、富马酸、甲苯磺酸、甲磺酸、乙烷二磺酸、草酸、羟乙基磺酸、三氟乙酸等制备的盐。
如果本发明化合物为酸性的,则适当的“药学上可接受的盐”指通过药学上可接受的无毒碱包括无机碱及有机碱制备的盐.得自无机碱的盐包括铝盐、铵盐、钙盐、铜盐、铁盐、亚铁盐、锂盐、镁盐、锰盐、亚锰盐、钾盐、钠盐、锌盐等。特别优选铵盐、钙盐、镁盐、钾盐和钠盐。得自药学上可接受的有机无毒碱的盐,所述碱包括伯胺、仲胺和叔胺的盐,取代的胺包括天然存在的取代胺、环状胺及碱性离子交换树脂例如精氨酸、甜菜碱、咖啡因、胆碱、N,N′-二苄基乙二胺、二乙胺、2一二乙基氨基乙醇、2一二甲基氨基乙醇、氨基乙醇、乙醇胺、乙二胺、N一乙基吗啉、N一乙基哌啶、葡萄糖胺、氨基葡萄糖、组氨酸、羟钴胺、异丙基胺、赖氨酸、甲基葡萄糖胺、吗啉、哌嗪,哌啶、呱咤、多胺树脂、普鲁卡因、嘌呤、可可碱、三乙胺、三甲胺、三丙胺、氨基丁三醇等。
Berg等,“Pharmaceutical Salts,”J.Pharm.Sci.’1977:66:1-19更详细描述了上文所述药学上可接受的盐及其它典型的药学上可接受的盐的制备。
由于在生理条件下化合物中脱质子化的酸性部分例如竣基可为阴离子的,而这种带有的电荷然后可被内部带有阳离子的质子化了的或烷基化的碱性部分例如四价氮原子平衡抵消,所以应注意本发明化合物是潜在的内盐或两性离子。
除在文献中已知的或在实验程序中例证的标准方法外,可采用如下列方案中显示的反应制备本发明化合物。因此,下列说明性方案是为说明的目的而不是局限于所列化合物或任何特定的取代基。方案中显示的取代基数目并不必需符合权利要求中所用的数目,且为清楚起见,显示单取代基连接到在上文中式I~II的定义下允许有多取代基的化合物上。
方案
如发明所述式I-IV化合物,本领域的技术人员可以根据现有技术和所具备的常识,可以由4-氯-2-甲巯基嘧啶-5-碳酸乙酯为起始原料通过9步反应合成。
在一个实施方案中,本申请提供了一种利用具有式I-IV的化合物及其药学可接受的盐治疗人或其它哺乳动物肿瘤等过渡增殖性疾病或症状。
在一个实施方案中,本申请所设计的化合物及其药学可接受的盐可以用于治疗或控制非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、胰腺癌、乳腺癌、前列腺癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌、鼻咽癌等过渡增殖性疾病。
药物代谢物及前药
本申请所涉及的化合物及其药学可接受的盐的代谢产物,以及可以在体内转变为本申请所涉及的化合物及其药学可接受的盐的结构的前药,也包含在本申请的权利要求中。
联合用药
式I-IV化合物可以与已知的治疗或改进相似病状的其它药物联用。联合给药时,原来药物的给药方式&剂量保持不变,而同时或随后服用式I-IV化合物。当式I-IV化合物与其它一种或几种药物同时服用时,优选使用同时含有一种或几种已知药物和式I化合物的药用组合物。药物联用也包括在重叠的时间段服用式I-IV化合物与其它一种或几种已知药物。当式I-IV化合物与其它一种或几种药物进行药物联用时,式I-IV化合物或已知药物的剂量可能比它们单独用药时的剂量较低。
可以与式I-IV化合物进行药物联用的药物或活性成分包括但不局限为:
雌激素受体调节剂、雄激素受体调节剂、视网膜样受体调节剂、细胞毒素/细胞抑制剂、抗增殖剂、蛋白转移酶抑制剂、HMG-CoA还原酶抑制剂、HIV蛋白激酶抑制剂、逆转录酶抑制剂、血管生成抑制剂、细胞增殖及生存信号抑制剂、干扰细胞周期关卡的药物和细胞凋亡诱导剂,细胞毒类药物、酪氨酸蛋白抑制剂、EGFR抑制剂、VEGFR抑制剂、丝氨酸/苏氨酸蛋白抑制剂、Bcr-Abl抑制剂,c-Kit抑制剂,Met抑制剂,Raf抑制剂,MEK抑制剂,MMP抑制剂,拓扑异构酶抑制剂、组氨酸去乙酰化酶抑制剂、蛋白酶体抑制剂、CDK抑制剂,Bcl-2家族蛋白抑制剂,MDM2家族蛋白抑制剂、IAP家族蛋白抑制剂、STAT家族蛋白抑制剂、PI3K抑制剂、AKT抑制剂、整联蛋白阻滞剂、干扰素-α、白介素-12、COX-2抑制剂、p53、p53激活剂、VEGF抗体、EGF抗体等。
在一个实施方案中,可以与式I-IV化合物进行药物联用的药物或活性成分包括但不局限为:阿地白介素、阿仑膦酸、干扰素、阿曲诺英、别嘌醇、别嘌醇钠、帕洛诺司琼盐酸盐、六甲蜜胺、氨基格鲁米特、氨磷汀、氨柔比星、安丫啶、阿纳托唑、多拉司琼、aranesp、arglabin、三氧化二砷、阿诺新、5-氮胞苷、硫唑嘌呤、卡介苗或tice卡介苗、贝他定、醋酸倍他米松、倍他米松磷酸钠制剂、贝沙罗汀、硫酸博来霉素、溴尿甘、bortezomib、白消安、降钙素、阿来佐单抗注射剂、卡培他滨、卡铂、康士得、cefesone、西莫白介素、柔红霉素、苯丁酸氮芥、顺铂、克拉屈滨、克拉屈滨、氯屈磷酸、环磷酰胺、阿糖胞昔、达卡巴嗪、放线菌素D、柔红霉素脂质体、地塞米松、磷酸地塞米松、戊酸雌二醇、地尼白介素2、狄波美、地洛瑞林、地拉佐生、己烯雌酚、大扶康、多西他奇、去氧氟尿苷、阿霉素、屈大麻酚、钦-166-壳聚糖复合物、eligard、拉布立酶、盐酸表柔比星、阿瑞吡坦、表阿霉素、阿法依伯汀、红细胞生成素、依铂、左旋咪唑片、雌二醇制剂、17-β-雌二醇、雌莫司汀磷酸钠、炔雌醇、氨磷汀、羟磷酸、凡毕复、依托泊甙、法倔唑、他莫昔芬制剂、非格司亭、非那司提、非雷司替、氟尿苷、氟康唑、氟达拉滨、5-氟脱氧尿嘧啶核苷一磷酸盐、5-氟尿嘧啶、氟甲睾酮、氟他胺、福麦斯坦、1-β-D-阿糖呋喃糖胞噻啶-5’-硬脂酰磷酸酯、福莫司汀、氟维司群、丙种球蛋白、吉西他滨、吉妥单抗、甲磺酸伊马替尼、卡氮芥糯米纸胶囊剂、戈舍瑞林、盐酸格拉尼西隆、组氨瑞林、和美新、氢化可的松、赤型-羟基壬基腺嘌呤、羟基脲、替坦异贝莫单抗、伊达比星、异环磷酰胺、干扰素α、干扰素-α2、干扰素α-2A、干扰素α-2B、干扰素α-n1、干扰素α-n3、干扰素β、干扰素γ-la、白细胞介素-2、内含子A、易瑞沙、依立替康、凯特瑞、硫酸香菇多糖、来曲唑、甲酰四氢叶酸、亮丙瑞林、亮丙瑞林醋酸盐、左旋四咪唑、左旋亚叶酸钙盐、左甲状腺素钠、左甲状腺素钠制剂、洛莫司汀、氯尼达明、屈大麻酚、氮芥、甲钴胺、甲羟孕酮醋酸酯、醋酸甲地孕酮、美法仑、酯化雌激素、6-琉基嘌呤、美司钠、氨甲蝶呤、氨基乙酰丙酸甲酯、米替福新、美满霉素、丝裂霉素C、米托坦、米托葱醌、曲洛司坦、柠檬酸阿霉素脂质体、奈达铂、聚乙二醇化非格司亭、奥普瑞白介素、neupogen、尼鲁米特、三苯氧胺、NSC-631570、重组人白细胞介素1-β、奥曲肽、盐酸奥丹西隆、去氢氢化可的松口服溶液剂、奥沙利铂、紫杉醇、泼尼松磷酸钠制剂、培门冬酶、派罗欣、喷司他丁、溶链菌制剂、盐酸匹鲁卡品、毗柔比星、普卡霉素、卟吩姆钠、泼尼莫司汀、司替泼尼松龙、泼尼松、倍美力、丙卡巴脐、重组人类红细胞生成素、雷替曲塞、利比、依替膦酸铼-186、美罗华、力度仲-A、罗莫肽、盐酸毛果芸香碱片剂、奥曲肽、沙莫司亭、司莫司汀、西佐喃、索布佐生、唬钠甲强龙、帕福斯酸、干细胞治疗、链佐星、氯化锶-89、左旋甲状腺素钠、他莫昔芬、坦舒洛辛、他索那明、tastolactone、泰索帝、替西硫津、替莫唑胺、替尼泊苷、丙酸睾酮、甲睾酮、硫鸟嘌呤、噻替哌、促甲状腺激素、替鲁膦酸、拓扑替康、托瑞米芬、托西莫单抗、曲妥珠单抗、曲奥舒凡、维A酸、甲氨喋呤片剂、三甲基密胺、三甲曲沙、乙酸曲普瑞林、双羟萘酸曲普瑞林、优福定、尿苷、戊柔比星、维司力农、长春碱、长春新碱、长春酰胺、长春瑞滨、维鲁利秦、右旋丙亚胺、净司他丁斯酯、枢复宁、紫杉醇蛋白质稳定制剂、acolbifene、干扰素r-lb、affinitak、氨基喋呤、阿佐昔芬、asoprisnil、阿他美坦、阿曲生坦、BAY 43-9006、阿瓦斯丁、CCI-779、CDC-501、西乐葆、西妥昔单抗、克立那托、环丙孕酮醋酸酯、地西他滨、DN-101、阿霉素-MTC、dSLIM、度他雄胺、edotecarin、依氟鸟氨酸、依喜替康、芬维A胺、组胺二盐酸盐、组氨瑞林水凝胶植入物、钬-166DOTMP、伊班膦酸、干扰素γ、内含子-PEG、ixabepilone、匙孔形血蓝蛋白、L-651582、兰乐肽、拉索昔芬、libra、lonafamib、米泼昔芬、米诺屈酸酯、MS-209、脂质体MTP-PE、MX-6、那法瑞林、奈莫柔比星、新伐司他、诺拉曲特、奥利默森、onco-TCS、osidem、紫杉醇聚谷氨酸酯、帛米酸钠、PN-401、QS-21、夸西洋、R-1549、雷洛昔芬、豹蛙酶、13-顺维A酸、沙铂、西奥骨化醇、T-138067、tarceva、二十二碳六烯酸紫杉醇、胸腺素αl、嘎唑呋林、tipifarnib、替拉扎明、TLK-286、托瑞米芬、反式MID-lo7R、伐司朴达、伐普肽、vatalanib、维替泊芬、长春氟宁、Z-100和唑来麟酸或它们的组合。
以下实施例对本发明做进一步的描述,但该实施例并非用于限制本发明的保护范围。
实施例1
N-(3-(3-甲基-7-(甲氨基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF21)
(N-(3-(3-methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide)
步骤1.4-(3-叔丁氧羰基氨基苯胺)-2-甲巯基嘧啶-5-碳酸乙酯
(ethyl 4-(3-(tert-butoxycarbonylamino)phenylamino)-2-(methylthio)pyrimidine-5-carboxylate)
4-氯-2-甲巯基嘧啶-5-碳酸乙酯(23.3g,100mmol),N-Boc间苯二胺(20.8g,1.0eq),K2CO3(27.6g,2.0eq)溶于300ml无水DMF中,氮气保护下,加热至80℃,搅拌过夜。冷却至室温,搅拌下加入1000ml冰水,大量固体析出。减压过滤,真空干燥得白色固体38.8g(96%)。
1H NMR(400Hz,CDCl3)δ10.37(s,1H),8.76(s,1H),7.90(s,1H),7.34(d,J=8.0Hz,1H),7.24(t,J=8.0Hz,1H),7.02(d,J=8.0Hz,1H),6.53(s,1H),4.38(q,J=7.2,14.4Hz,2H),2.55(s,3H),1.52(s,9H),1.40(t,J=7.2Hz,3H).
步骤2.(叔丁基-3-(5-(羟甲基)-2-(甲巯基)嘧啶-4-取代氨基)苯甲酰胺碳酸酯)(tert-butyl 3-(5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-ylamino)phenylcarbamate)
4-(3-叔丁氧羰基氨基苯胺)-2-甲巯基嘧啶-5-碳酸乙酯(20.2g,50mmol)溶于500ml无水THF,冷却至-40℃,2M的四氢铝锂(50ml,2.0eq)慢慢滴加到上述反应液中,升温至室温,继续搅拌2h。冰浴下,滴加20ml甲醇淬灭反应,加饱和NaHCO3溶液使氢氧化铝析出,使用硅藻土减压过滤,浓缩溶剂,柱层析分离得黄色固体10.33g(57%)。
1H NMR(400Hz,CDCl3)δ8.02(s,1H),7.86(s,1H),7.80(s,1H),7.36(dd,J=1.2,8.0Hz,1H),7.22(t,J=8.0Hz,1H),6.95(dd,J=1.2,8.0Hz,1H),6.52(s,1H),4.61(s,2H),2.52(s,3H),1.52(s,9H).
步骤3.(叔丁基-3-(5-(甲酰基)-2-(甲巯基)嘧啶-4-取代氨基)苯甲酰胺碳酸酯)
(tert-butyl 3-(5-formyl-2-(methylthio)pyrimidin-4-ylamino)phenylcarbamate)
叔丁基-3-(5-(羟甲基)-2-(甲巯基)嘧啶-4-取代氨基)苯甲酰胺碳酸酯(10g,27.6mmol)溶于300ml DCM中,分批加入活性MnO2(24g,10eq),室温搅拌过夜。使用硅藻土减压过滤,加压下蒸发溶剂得黄色固体8.36g(84%)。
1H NMR(400Hz,CDCl3)δ10.61(s,1H),9.77(s,1H),8.43(s,1H),7.98(s,1H),7.36(dd,J=0.8,8.0Hz,1H),7.25-7.29(m,1H),7.03(dd,J=1.2,8.0Hz,1H),6.51(s,1H),2.59(s,3H),1.53(s,9H).
步骤4.(叔丁基-3-(5-((甲氨基)甲基)-2-(甲巯基)嘧啶-4-取代氨基)苯甲酰胺碳酸酯)(tert-butyl3-(5-((methylamino)methyl)-2-(methylthio)pyrimidin-4-ylamino)Phenylcarbamate)
叔丁基-3-(5-(甲酰基)-2-(甲巯基)嘧啶-4-取代氨基)苯甲酰胺碳酸酯(7.21g,20mmol)溶于200ml MeOH中,冷却0℃,加入甲胺盐酸盐(6.75g,5.0eq),醋酸钠(8.2g,5.0eq),移至室温搅拌1h。冷却0℃,分批加入NaBH4(1.51g,2.0eq),移至室温搅拌过夜。浓缩溶液,DCM萃取,饱和NaHCO3溶液洗涤,饱和食盐水洗涤,无水Na2SO4干燥,组层析得白色固体5.25g(71%)。
1H NMR(400Hz,CDCl3)δ10.12(s,1H),7.89(s,1H),7.78(s,1H),7.35(d,J=8.8Hz,1H),7.21(t,J=8.0Hz,1H),6.97(dd,J=1.2,8.0Hz,1H),6.50(s,1H),3.74(s,2H),3.55(s,3H),2.44(d,J=0.4Hz,3H),1.52(s,9H).
步骤5.(叔丁基-3-(3-甲基-7-(甲巯基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯甲酰胺碳酸酯)
(tert-butyl 3-(3-methyl-7-(methylthio)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenylcarbamate)
叔丁基-3-(5-((甲氨基)甲基)-2-(甲巯基)嘧啶-4-取代氨基)苯甲酰胺碳酸酯(5.2g,13.8mmol),DIEA(8ml,4.0eq)溶于140ml THF中,冷却至0℃。慢慢滴加0.2M的三光气THF溶液(25ml,1.1/3eq),移至室温搅拌1h。浓缩溶剂,DCM萃取,水洗三次,饱和食盐水洗一次,无水Na2SO4干燥,减压下蒸发溶剂,乙酸乙酯重结晶得白色固体4.71g(85%)。
1H NMR(400Hz,CDCl3)δ8.10(s,1H),7.44(s,1H),7.34(t,J=8.0Hz,1H),7.23(d,J=7.2Hz,1H),6.90(d,J=8.0Hz,1H),6.55(s,1H),4.46(s,2H),3.08(s,3H),2.14(s,3H),1.50(s,9H).
步骤6.(叔丁基-3-(3-甲基-7-(甲砜基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯甲酰胺碳酸酯)
(tert-butyl 3-(3-methyl-7-(methylsulfonyl)-2-oxo-3,4-dihydropyrimido[4,5-d]Pyrimidin-1(2H)-yl)phenylcarbamate)
叔丁基-3-(3-甲基-7-(甲巯基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯甲酰胺碳酸酯(4.0g,10mmol)溶于100mlDCM中,冷却至0℃,分批加入85%的MCPBA(6.1g,3.0eq,),室温搅拌3h。DCM稀释,饱和NaHCO3溶液洗涤3次,饱和食盐水洗一次,无水Na2SO4干燥,减压下蒸发溶剂,乙酸乙酯重结晶得白色固体3.9g(90%)
1H NMR(400Hz,CDCl3)δ8.45(s,1H),7.58(s,1H),7.35(t,J=8.0Hz,1H),7.15(dd,J=1.2,8.0Hz,1H),6.89(dd,J=1.2,8.0Hz,1H),6.67(s,1H),4.62(s,2H),3.11(s,3H),2.98(s,3H),1.48(s,9H).
步骤7.(叔丁基-3-(3-甲基-7-(甲氨基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯甲酰胺碳酸酯)
(tert-butyl 3-(3-methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenylcarbamate)
叔丁基-3-(3-甲基-7-(甲砜基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯甲酰胺碳酸酯(260mg,0.6mmol)溶于1ml二氧六环中,加入甲胺盐酸盐(405mg,10eq),醋酸钠(492mg,10eq),加热至100℃封管反应24h。DCM稀释,饱和NaHCO3溶液洗涤,饱和食盐水洗一次,无水Na2SO4干燥,减压下蒸发溶剂,柱层析得白色固体205mg(89%)。
1H NMR(400Hz,CDCl3)δ7.93(s,1H),7.39(s,1H),7.32(t,J=8.0Hz,1H),7.23(s,1H),6.91(d,J=8.0Hz,1H),6.52(s,1H),4.36(s,2H),3.54(m,4H),3.06(s,3H),2.31(m,4H),2.56(s,3H),1.49(s,9H).
步骤8.1-(3-氨基苯基)-3-甲基-7-(甲氨基)-3,4-二氢嘧啶[4,5-d]嘧啶-2(1氢)-酮(1-(3-aminophenyl)-3-methyl-7-(methylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one)
叔丁基-3-(3-甲基-7-(甲氨基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯甲酰胺碳酸酯(205mg,0.53mmol)溶于1ml DCM中,加入0.4ml TFA(10eq),室温搅拌4h。减压浓缩溶剂,DCM稀释,饱和NaHCO3溶液洗涤,饱和食盐水洗一次,无水Na2SO4干燥,减压下蒸发溶剂,得黄色固体140mg(93%)。
步骤9.N-(3-(3-甲基-7-(甲氨基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF21)
(N-(3-(3-methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide)
1-(3-氨基苯基)-3-甲基-7-(甲氨基)-3,4-二氢嘧啶[4,5-d]嘧啶-2(1氢)-酮(128mg,0.45mmol)溶于2ml DCM,加入DIEA 65μl(1.0eq),冷却至0℃,移取丙烯酰氯37μl(1.0eq)慢慢滴加到上述反应液中,室温搅拌1h。减压蒸发溶剂,柱层析得白色固体114mg(75%)。
1H NMR(400Hz,DMSO-d6)δ10.23(s,1H),8.01(s,1H),7.61(d,J=8.0Hz,1H),7.55(s,1H),7.36(t,J=8.0Hz,1H),6.91(d,J=7.6Hz,1H),6.71(s,1H),6.43(dd,J=10.0,16.8Hz,1H),6.25(d,J=16.8Hz,1H),5.76(d,J=10.4Hz,1H),4.37(s,2H),2.93(s,3H),2.59(s,3H).LCMS(ESI):m/z 339.1[M+H]+.
实施例2
N-(3-(3-甲基-2-氧-7-(苯胺基)-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF10)
N-(3-(3-methyl-2-oxo-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例1。
1H NMR(400Hz,DMSO-d6)δ10.30(s,1H),9.41(s,1H),8.18(s,1H),7.43(d,J=8.0Hz,1H),7.66(s,1H),7.45(t,J=8.0Hz,1H),7.27(d,J=8.0Hz,2H),6.99(d,J=8.0Hz,1H),6.93(t,J=7.6Hz,2H),6.75(t,J=7.2Hz,1H),6.42(dd,J=10.4,16.8Hz,1H),6.24(d,J=16.8Hz,1H),5.75(d,J=10.4Hz,1H),4.48(s,2H),2.97(s,3H).
LCMS(ESI):m/z 401.1[M+H]+.
实施例3
N-(3-(3-甲基-7-(4-甲基哌嗪-1-取代)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF19)
N-(3-(3-methyl-7-(4-methylpiperazin-1-yl)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例1。
1H NMR(400Hz,DMSO-d6)δ8.25(s,1H),7.95(s,1H),7.53(s,1H),7.38(d,J=7.6Hz,1H),7.23-7.27(m,1H),6.88(d,J=7.6Hz,1H),6.32(d,J=16.4Hz,1H),6.12(dd,J=10.0,16.4Hz,1H),5.64(d,J=10.0Hz,1H),4.41(s,2H),3.52(m,4H),3.10(s,3H),2.30(m,4H),2.25(s,3H).LCMS(ESI):m/z 408.2[M+H]+.
实施例4
N-(3-(7-(2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF06)
N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
如同方案步骤7:
叔丁基-3-(7-(2-甲氧基-4-(4-家哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)苯甲酰胺碳酸酯
tert-butyl 3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenylcarbamate
叔丁基-3-(3-甲基-7-(甲砜基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯甲酰胺碳酸酯(260mg,0.6mmol)溶于1ml 2-丁醇中,加入2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺(133mg,1.0eq),TFA(48μl,1.0eq),加热至110℃封管反应24h。DCM稀释,饱和NaHCO3溶液洗涤,饱和食盐水洗一次,无水Na2SO4干燥,减压下蒸发溶剂,柱层析得黄色固体151mg(44%)。
1H NMR(400Hz,CDCl3)δ7.99(s,1H),7.48(d,J=7.5Hz,1H),7.44(s,1H),7.41(t,J=8.0Hz,1H),7.35(s,1H),6.97(d,J=7.5Hz,1H),6.63(s,1H),6.42(d,J=2.0Hz,1H),6.16(d,J=6.4Hz,1H),4.42(s,2H),3.80(s,3H),3.22(m,4H),3.08(s,3H),2.79(m,4H),1.47(s,9H).
其他步骤如实施例1
N-(3-(7-(2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF06)
N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
1H NMR(400Hz,DMSO-d6)δ10.31(s,1H),8.11(s,1H),7.81(d,J=7.6Hz,1H),7.56(s,1H),7.48(s,1H),7.43(t,J=8.0Hz,1H),7.27(d,J=8.4Hz,1H),6.95(d,J=8.0Hz,1H),6.51(s,1H),6.44(dd,J=10.0,16.8Hz,1H),6.25(d,J=16.8Hz,1H),6.02(d,J=8.0Hz,1H),5.76(d,J=10.0Hz,1H),4.46(s,2H),3.76(s,3H),2.99(m,4H),2.96(s,3H),2.50(m,4H),2.22(s,3H).LCMS(ESI):m/z 529.2[M+H]+.
实施例5
N-(3-(7-(2-甲氧基-4-(哌啶-1-取代)苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF11)
N-(3-(7-(2-methoxy-4-(piperidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.30(s,1H),8.11(s,1H),7.82(d,J=8.0Hz,1H),7.56(s,1H),7.47(s,1H),7.43(t,J=8.0Hz,1H),7.25(d,J=8.0Hz,1H),6.95(d,J=8.0Hz,1H),6.49(d,J=2.2Hz,1H),6.43(dd,J=8.0,16.0Hz,1H),6.25(dd,J=1.6,8.0Hz,1H),6.02(d,J=7.4Hz,1H),5.76(dd,J=1.6,8.0Hz,1H),4.46(s,2H),3.75(s,3H),2.96(m,7H),1.59(m,4H),1.49-1.504(m,2H).
LCMS(ESI):m/z 514.2[M+H]+.
实施例6
N-(3-(7-(2-甲氧基-4-(吡咯-1-取代)苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF12)
N-(3-(7-(2-methoxy-4-(pyrrolidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.31(s,1H),8.07(s,1H),7.77(d,J=8.0Hz,1H),7.59(s,1H),7.41(t,J=8.0Hz,1H),7.15(d,J=8.0Hz,1H),6.95(d,J=8.0Hz,1H),6.44(dd,J=10.0,16.8Hz,1H),6.25(d,J=16.4Hz,1H),6.10(s,1H),5.76(d,J=10.0Hz,2H),4.44(s,2H),3.74(s,3H),3.14(m,4H),2.96(s,3H),1.92(m,4H).
LCMS(ESI):m/z 500.2[M+H]+.
实施例7
N-(3-(7-(2-甲氧基-4-吗啡啉苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF08)
N-(3-(7-(2-methoxy-4-morpholinophenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.30(s,1H),8.12(s,1H),7.81(d,J=6.8Hz,1H),7.56(s,1H),7.50(s,1H),7.43(t,J=8.0Hz,1H),7.28(d,J=10.0Hz,1H),6.96(d,J=10.0Hz,1H),6.52(d,J=2.0Hz,1H),6.43(dd,J=10.0,16.8Hz,1H),6.22-6.27(m,1H),6.02(d,J=8.0Hz,1H),5.74-5.77(m,1H),4.46(s,2H),3.76(s,3H),3.71(t,J=4.4Hz,4H),2.96(m,7H).LCMS(ESI):m/z 516.2[M+H]+.
实施例8
N-(3-(7-(2-甲氧基-4-硫啡啉苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF09)
N-(3-(7-(2-methoxy-4-thiomorpholinophenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.31(s,1H),8.11(s,1H),7.82(d,J=7.6Hz,1H),7.56(s,1H),7.51(s,1H),7.43(t,J=8.0Hz,1H),7.27(d,J=8.8Hz,1H),6.97(d,J=7.6Hz,1H),6.49(d,J=2.0Hz,1H),6.43(dd,J=10.0,16.8Hz,1H),6.26(dd,J=2.0,16.8Hz,1H),6.02(d,J=7.6Hz,1H),5.75-5.77(m,1H),4.45(s,2H),3.76(s,3H),3.33(t,J=4.8Hz,4H),2.96(s,3H),2.65(t,J=4.8Hz,4H).
LCMS(ESI):m/z 532.2[M+H]+.
实施例9
N-(3-(7-(2-甲氧基-4-(4-(4-甲基哌嗪-1-取代)哌啶-1-取代)苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF14)
N-(3-(7-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.38(s,1H),8.11(s,1H),7.84(d,J=8.0Hz,1H),7.56(s,1H),7.48(s,1H),7.42(t,J=8.0Hz,1H),7.25(d,J=9.2Hz,1H),6.95(d,J=7.6Hz,1H),6.50(s,1H),6.46(dd,J=10.0,16.8Hz,1H),6.25(d,J=16.4Hz,1H),6.04(s,1H),5.75(d,J=7.2Hz,1H),4.45(s,2H),3.75(s,3H),3.55(d,J=10.8Hz,2H),3.37-3.43(m,1H),2.96-3.01(m,5H),2.50-2.60(m,8H),2.29(s,3H),1.82(d,J=10.8Hz,2H),1.44-1.52(m,2H).
LCMS(ESI):m/z 612.3[M+H]+.
实施例10
N-(3-(7-(4-(4-(二甲氨基)哌啶-1-取代)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF13)
N-(3-(7-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.34(s,1H),8.11(s,1H),7.84(d,J=7.6Hz,1H),7.55(s,1H),7.48(s,1H),7.42(t,J=8.0Hz,1H),7.25(d,J=8.4Hz,1H),6.95(d,J=7.2Hz,1H),6.51(s,1H),6.45(dd,J=10.0,17.2Hz,1H),6.25(d,J=16.8Hz,1H),6.04(s,1H),5.76(d,J=9.6Hz,1H),4.46(s,2H),3.75(s,3H),3.56(d,J=12.4Hz,2H),3.35(s,3H),2.87(m,1H),2.49-2.56(m,2H),2.34(s,6H),1.86(d,J=10.4Hz,2H),1.46-1.55(m,2H).
LCMS(ESI):m/z 557.2[M+H]+.
实施例11
N-(3-(7-(2-甲氧基-4-(4-甲基-1,4-二氮杂环庚烷-1-取代)苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF17)
N-(3-(7-(2-methoxy-4-(4-methyl-1,4-diazepan-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.30(s,1H),8.19(s,1H),7.85(s,1H),7.69-7.70(m,2H),7.51(t,J=8.0Hz,1H),7.45(t,J=8.0Hz,1H),6.96-6.99(m,2H),6.40-6.46(m,2H),6.24(dd,J=1.6,16.8Hz,1H),5.75(dd,J=1.6,10.0Hz,1H),4.50(s,2H),3.33(m,7H),2.98(s,3H),2.74(t,J=4.4Hz,4H),2.49(m,2H),2.24(s,3H).
LCMS(ESI):m/z 543.2[M+H]+.
实施例12
(R)-N-(3-(7-(4-(3-(二甲氨基)吡咯-1-取代)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF15)
(R)-N-(3-(7-(4-(3-(dimethylamino)pyrrolidin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.47(s,1H),8.07(s,1H),7.85(d,J=8.0Hz,1H),7.57(s,1H),7.38-7.42(m,2H),7.21(d,J=8.4Hz,1H),6.93(d,J=7.6Hz,1H),6.50(dd,J=10.0,16.8Hz,1H),6.26(d,J=16.8Hz,1H),6.11(s,1H),5.74(d,J=10.8Hz,1H),4.44(s,2H),3.75(s,3H),3.35(t,J=8.0Hz,2H),3.27(t,J=8.0Hz,2H),3.11-3.17(m,1H),2.96(s,3H),2.30(s,6H),2.14-2.19(m,1H),1.18-1.89(m,1H).
LCMS(ESI):m/z 543.2[M+H]+.
实施例13
(S)N-(3-(7-(4-(3-(二甲氨基)吡咯-1-取代)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF16)
(S)N-(3-(7-(4-(3-(dimethylamino)pyrrolidin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
LCMS(ESI):m/z 543.2[M+H]+.
实施例14
N-(3-(7-(4-(4-乙酰基哌嗪-1-取代)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF20)
N-(3-(7-(4-(4-acetylpiperazin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ8.26(s,1H),7.99(s,1H),7.96(s,1H),7.47(s,1H),7.40(t,J=8.0Hz,2H),7.17(s,1H),6.95(d,J=8.0Hz,1H),6.40(s,1H),6.34(d,J=16.4Hz,1H),6.10-6.18(m,2H),5.65(d,J=9.6Hz,1H),4.43(s,2H),3.79(s,3H),3.73(t,J=4.8Hz,2H),3.58(t,J=4.8Hz,2H),3.06(s,3H),2.99-3.02(m,4H),2.13(s,3H).
LCMS(ESI):m/z 557.2[M+H]+.
实施例15
N-(3-(7-(4-(二甲氨基)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF23)
N-(3-(7-(4-(dimethylamino)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.29(s,1H),8.09(s,1H),7.79(d,J=8.8Hz,1H),7.57(s,1H),7.40(t,J=8.0Hz,2H),7.17(s,1H),6.95(d,J=8.0Hz,1H),6.40(s,1H),6.34(d,J=16.4Hz,1H),6.10-6.18(m,2H),5.65(d,J=9.6Hz,1H),4.43(s,2H),3.79(s,3H),3.73(t,J=4.8Hz,2H),3.58(t,J=4.8Hz,2H),3.06(s,3H),2.99-3.02(m,4H),2.13(s,3H).
LCMS(ESI):m/z 474.2[M+H]+.
实施例16
N-(3-(7-(2-氟-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF18)
N-(3-(7-(2-fluoro-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.30(s,1H),8.19(s,1H),7.86(s,1H),7.69-7.70(m,2H),7.51(t,J=8.0Hz,1H),7.45(t,J=8.0Hz,1H),6.96-6.99(m,2H),6.43(dd,J=10.0,17.2Hz,1H),6.39-6.43(m,1H),6.24(dd,J=2.0,17.2Hz,1H),5.75(dd,J=2.0,10.0Hz,1H),4.50(s,2H),3.98(s,3H),3.74(t,J=4.4Hz,4H),2.48(m,4H),2.24(s,3H).
LCMS(ESI):m/z 517.2[M+H]+.
实施例17
N-(3-(7-(2-甲氧基-4-(2-甲氧基乙氧基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF22)
N-(3-(7-(2-methoxy-4-(2-methoxyethoxy)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.30(s,1H),8.12(s,1H),7.75(d,J=7.6Hz,1H),7.61(s,1H),7.54(s,1H),7.43(t,J=8.0Hz,1H),7.30(d,J=8.4Hz,1H),6.96(d,J=7.6Hz,1H),6.52(d,J=2.0Hz,1H),6.43(dd,J=10.0,16.8Hz,1H),6.25(dd,J=1.2,16.8Hz,1H),6.04(d,J=8.4Hz,1H),5.75(dd,J=1.2,10.0Hz,1H),4.46(s,2H),3.97(t,J=4.0Hz,2H),3.76(s,3H),3.61(t,J=4.4Hz,2H),3.30(s,3H),2.96(s,3H).
LCMS(ESI):m/z 505.0[M+H]+.
实施例18
N-(3-(3-异丙基-7-(2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF24)
N-(3-(3-isopropyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.32(s,1H),8.14(s,1H),7.80(d,J=6.8Hz,1H),7.57(s,1H),7.48(s,1H),7.42(t,J=8.0Hz,1H),7.29(d,J=7.6Hz,1H),6.97(d,J=8.0Hz,1H),6.52(s,1H),6.43(dd,J=10.0,17.2Hz,1H),6.25(d,J=16.8Hz,1H),6.04(d,J=9.2Hz,1H),5.76(d,J=10.4Hz,1H),4.52-4.55(m,1H),4.37(s,2H),3.76(s,3H),3.04(m,4H),2.57(m,4H),2.32(s,3H),1.19(d,J=6.8Hz,6H).
LCMS(ESI):m/z 557.2[M+H]+.
实施例19
N-(3-(7-(2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-(4-甲氧基苯)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF25)
N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-(4-methoxyphenyl)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.33(s,1H),8.15(s,1H),7.81(d,J=7.2Hz,1H),7.66(s,1H),7.56(s,1H),7.45(t,J=8.0Hz,1H),7.36(d,J=8.4Hz,2H),7.30(d,J=8.8Hz,1H),7.05(d,J=7.6Hz,1H),6.97(d,J=8.4Hz,2H),6.52(s,1H),6.44(dd,J=10.0,17.2Hz,1H),6.26(d,J=16.8Hz,1H),6.05(s,1H),5.76(d,J=9.6Hz,1H),4.81(s,2H),3.77(s,6H),3.01(m,4H),2.44(m,4H),2.23(s,3H).
LCMS(ESI):m/z 621.2[M+H]+.
实施例20
N-(3-(3-环丙基-7-(2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(C-EGF26)
N-(3-(3-cyclopropyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400Hz,DMSO-d6)δ10.31(s,1H),8.12(s,1H),7.81(d,J=7.6Hz,1H),7.55(s,1H),7.48(s,1H),7.43(t,J=8.0Hz,1H),7.27(d,J=7.6Hz,1H),6.96(d,J=7.6Hz,1H),6.50(s,1H),6.43(dd,J=10.0,17.2Hz,1H),6.25(d,J=16.8Hz,1H),6.03(s,1H),5.76(d,J=10.0Hz,1H),4.43(s,2H),3.75(s,3H),3.00(m,4H),2.67(m,1H),2.46(m,4H),2.24(s,3H),0.76(d,J=5.6Hz,2H),0.68(s,2H).
LCMS(ESI):m/z 555.2[M+H]+.
实施例21
N-(3-(3-甲基-7-(4-(4-4-甲基哌嗪-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x001)
N-(3-(3-methyl-7-(4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,DMSO)δ10.31(s,1H),9.17(s,1H),8.13(s,1H),7.84(d,J=8.0Hz,1H),7.56(s,1H),7.44(t,J=8.0Hz,1H),7.12(d,J=7.2Hz,2H),6.96(d,J=7.6Hz,1H),6.53(d,J=8.0Hz,2H),6.43(dd,J=16.4,9.6Hz,1H),6.25(d,J=16.4Hz,1H),5.76(d,J=10.0Hz,1H),4.46(s,2H),2.97(s,3H),2.92(s,4H),2.41(s,4H),2.20(s,3H).
LCMS(ESI):m/z 499.2[M+H]+.
实施例22
N-(3-(3-甲基-2-氧-7-(4-(哌啶-1-取代)苯胺基)-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x002)
N-(3-(3-methyl-2-oxo-7-(4-(piperidin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,DMSO)δ10.31(s,1H),9.16(s,1H),8.12(s,1H),7.85(d,J=7.2Hz,1H),7.56(s,1H),7.44(t,J=8.0Hz,1H),7.10(d,J=7.6Hz,2H),6.96(d,J=7.2Hz,1H),6.52(d,J=8.0Hz,2H),6.43(dd,J=16.8,9.6Hz,1H),6.25(d,J=17.6Hz,1H),5.75(d,J=10.0Hz,1H),4.45(s,2H),2.96(s,3H),2.90(s,4H),1.57(s,4H),1.47(d,J=5.2Hz,2H).
LCMS(ESI):m/z 484.1[M+H]+.
实施例23
N-(3-(3-甲基-7-(4-(4-(4-甲基哌嗪-1-取代)哌啶-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x003)
N-(3-(3-methyl-7-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,DMSO)δ10.31(s,1H),9.15(s,1H),8.12(s,1H),7.85(d,J=8.8Hz,1H),7.55(s,1H),7.43(t,J=8.0Hz,1H),7.10(d,J=8.4Hz,2H),6.96(d,J=8.4Hz,1H),6.53(d,J=8.0Hz,2H),6.43(dd,J=17.0,9.0Hz,1H),6.23-6.27(m,1H),5.76(d,J=11.6Hz,1H),4.45(s,2H),3.47(d,J=11.6Hz,2H),3.33(s,3H),2.97(s,3H),2.33-2.50(m,7H),2.21(s,4H),1.79(d,J=11.6Hz,2H),1.41-1.49(m,2H).
LCMS(ESI):m/z 582.2[M+H]+.
实施例24
N-(3-(7-(4-(4-(二甲氨基)哌啶-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x004)
N-(3-(7-(4-(4-(dimethylamino)piperidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,DMSO)δ10.31(s,1H),9.17(s,1H),8.12(s,1H),7.85(d,J=7.6Hz,1H),7.55(s,1H),7.44(t,J=8.0Hz,1H),7.10(d,J=6.0Hz,2H),6.96(d,J=7.6Hz,1H),6.53(d,J=7.2Hz,2H),6.39(dd,J=16.8,10.4Hz,1H),6.25(d,J=16.4Hz,1H),5.76(d,J=9.6Hz,1H),4.45(s,2H),3.45(d,J=11.6Hz,2H),2.96(s,3H),2.45(d,J=11.2Hz,2H),2.18(s,7H),1.78(d,J=11.2Hz,2H),1.41-1.46(m,2H).
LCMS(ESI):m/z 527.2[M+H]+.
实施例25
N-(3-(3-甲基-2-氧-7-(4-硫啡啉苯胺基)-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x005)
N-(3-(3-methyl-2-oxo-7-(4-thiomorpholinophenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,DMSO)δ10.31(s,1H),9.20(s,1H),8.13(s,1H),7.84(d,J=7.6Hz,1H),7.56(s,1H),7.44(t,J=7.8Hz,1H),7.13(d,J=7.2Hz,2H),6.96(d,J=7.6Hz,1H),6.53(d,J=8.4Hz,2H),6,43(dd,J=17.0Hz,9.8Hz,1H),6.25(d,J=16.8Hz,1H),5.76(d,J=10.0Hz,1H),4.46(s,2H),3.25-3.26(m,4H),2.97(s,3H),2.62-2.64(m,4H).
LCMS(ESI):m/z 502.1[M+H]+.
实施例26
N-(3-(7-(2-异丙氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x006)
N-(3-(7-(2-isopropoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,CDCl3)δ8.40(s,1H),7.96(s,1H),7.91(d,J=8.0Hz,1H),7.49(s,1H),7.37(t,J=8.0Hz,2H),7.25(s,1H),6.94(d,J=7.6Hz,1H),6.41(d,J=2.0Hz,1H),6.32(d,J=12.8Hz,1H),6.14-6.18(m,1H),6.08-6.11(m,1H),5.62(d,J=10.0Hz,1H),4.47-4.53(m,1H),4.39(s,2H),3.05(t,J=4.8Hz,4H),3.03(s,3H),2.56(t,J=4.6Hz,4H),2.34(s,3H),1.30(d,J=6.0Hz,6H).
LCMS(ESI):m/z 557.3[M+H]+.
实施例27
N-(3-(3-甲基-7-(4-吗啡啉苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x007)
N-(3-(3-methyl-7-(4-morpholinophenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,DMSO)δ10.31(s,1H),9.19(s,1H),8.13(s,1H),7.83(d,J=8.8Hz,1H),7.56(s,1H),7.44(t,J=8.0Hz,1H),7.14(d,J=7.6Hz,2H),6.96(d,J=7.2Hz,1H),6.54(d,J=7.6Hz,2H),6.43(dd,J=17.2,10.0Hz,1H),6.24(d,J=17.2Hz,1H),5.76(d,J=12.0Hz,1H),4.46(s,2H),3.70(t,J=4.4Hz,4H),2.97(s,3H),2.90(t,J=4.4Hz,4H).
LCMS(ESI):m/z 486.1[M+H]+.
实施例28
N-(3-(7-(2-甲氧基-4-(2-吗啡啉乙氧基)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x008)
N-(3-(7-(2-methoxy-4-(2-morpholinoethoxy)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,CDCl3)δ8.18(s,1H),8.00(s,1H),7.85(d,J=8.4Hz,1H),7.39-7.43(m,4H),6.99(d,J=7.6Hz,1H),6.37-6.39(m,2H),6.33(s,1H),6.18-6.24(m,1H),6.07-6.10(m,1H),5.67(d,J=10.4Hz,1H),4.45(s,2H),4.10(s,2H),3.80(s,4H),3.77(s,3H),3.09(s,3H),2.85(s,2H),2.68(s,4H).
LCMS(ESI):m/z 560.1[M+H]+.
实施例29
N-(3-(7-(2-乙氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x009)
N-(3-(7-(2-ethoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,CDCl3)δ8.28(s,1H),7.99(s,1H),7.93(d,J=7.6Hz,1H),7.48(s,1H),7.40(t,J=8.0Hz,2H),7.28(s,1H),6.96(d,J=8.0Hz,1H),6.38(s,1H),6.34(d,J=16.4Hz,1H),6.18(dd,J=16.8,10.0Hz,1H),6.10(d,J=8.4Hz,1H),5.65(d,J=10.4Hz,1H),4.42(s,2H),4.00(q,J=13.6,6.8Hz,2H),3.13(s,4H),3.06(s,3H),2.70(s,4H),2.44(s,3H),1.39(t,J=6.8Hz,3H).
LCMS(ESI):m/z 543.2[M+H]+.
实施例30
N-(3-(3-甲基-7-(2-甲基-4-(4-甲基哌嗪-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x010)
N-(3-(3-methyl-7-(2-methyl-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,CDCl3)δ8.35(s,1H),7.97(s,1H),7.62(d,J=7.6Hz,1H),7.45(s,1H),7.27-7.33(m,2H),6.91(d,J=8.0Hz,1H),6.64(s,1H),6.56(s,1H),6.49(d,J=8.0Hz,1H),6.33(d,J=16.8Hz,1H),6.17(dd,J=16.8,10.0Hz,1H),5.64(d,J=10.4Hz,1H),4.44(s,2H),3.14(s,4H),3.10(s,3H),2.65(s,4H),2.41(s,3H),2.14(s,3H).
LCMS(ESI):m/z 513.2[M+H]+.
实施例31
N-(3-(7-(3-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺(x011)
N-(3-(7-(3-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
合成方法如实施例4。
1H NMR(400MHz,DMSO)δ10.30(s,1H),9.13(s,1H),8.15(s,1H),7.79(d,J=8.4Hz,1H),7.58(s,1H),7.42(d,J=8.0Hz,1H),6.91-6.97(m,2H),6.86(s,1H),6.39-6.46(m,2H),6.24(d,J=16.8Hz,1H),5.75(d,J=10.0Hz,1H),4.46(s,2H),3.58(s,3H),2.96(s,3H),2.79(s,4H),2.39(s,4H),2.19(s,3H).
LCMS(ESI):m/z 529.2[M+H]+.
实施例32
7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物对EGFR野生型和EGFR-T790M突变的激酶EC50测试
激酶活性检测:应用Z′-LYTETM技术(采用荧光进行检测、酶偶联形式,以磷酸化和非磷酸化多肽对蛋白水解切割的敏感性差异为基础),采用荧光共振能量转移(FRET)原理,使用Z′LYTETM FRET肽类底物,二级反应检测化合物对激酶活性。(invitrogen,Z′-LYTETMKINASE ASSAY KIT-TYR 2PEPTIDE,PV3191)将EGFR-T790M激酶(invitrogen,PV4803)逐级稀释后加入FRET肽,ATP,再加入不同浓度化合物,反应1h后,加入位点特异性蛋白酶,识别并切割非磷酸化的FRET肽,反应1h,使用400nm激发波长,检测445nm及520nm吸收。
得出抑制率与药物浓度成正相关,做出激酶活性与浓度关系曲线,计算IC50值。
实施例表格Table1所列为化合物编号以及对应激酶活性结果。
Table1
7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物与ATP的竞争实验中,由于存在与蛋白半胱氨酸位点形成不可逆迈克尔加成反应,所以对两种激酶都体现出较高的抑制活性。见附图1-22。
实施例34
EGFR活性的细胞测试
MTT检测化合物对细胞增殖的影响:1500个/每孔,NCI-H820(肺癌细胞,EGFR野生型),A431(人表皮癌,EGFR高表达),HCC827(肺癌细胞,EGFR E746-A750 deletion),H1975(肺癌细胞,EGFR L858R&T790M)铺96孔板,24h后,用DMSO配制的不同浓度化合物处理(DMSO终浓度1‰,平行对照3-5个),72h后加入MTT(噻唑蓝,5mg/ml,10ul/孔),37度孵育4h。吸去上清,加入DMSO150ul,充分振荡后,检测OD570,使用GraphPad Prism4Demo软件处理。结果发现,7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物处理可明显降低上述细胞对MTT的吸收,说明7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物可显著抑制上述细胞的增殖,尤其是抑制H1975(L858R/T790),HCC827(DEL746-750)两类细胞的增值,抑制率与药物浓度成正相关。根据7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物对这些细胞的生长抑制作用,我们计算出其半数抑制浓度(IC50)值如Table2所描述。(所用化合物分别为实施例1-31所制备的化合物,在表中用实施例标号表示)。
CompdNo | H1975 | HCC827 | A431 | NCI-H820 |
C-EGF06 | 0.085 | 0.052 | 2.93 | >100 |
C-EGF08 | 0.159 | 0.159 | 21.2 | >100 |
C-EGF09 | 0.379 | 0.212 | 10.7 | >100 |
C-EGF10 | 0.213 | 0.028 | 1.58 | >100 |
C-EGF11 | 2.56 | 0.310 | 17.7 | >100 |
C-EGF12 | 1.53 | 0.409 | 8.16 | 35.6 |
C-EGF13 | 0.568 | 0.198 | >100 | >100 |
C-EGF14 | 1.22 | 0.188 | >100 | >100 |
C-EGF15 | - | - | - | - |
C-EGF16 | - | - | - | - |
C-EGF17 | 0.710 | 0.062 | 11.1 | >100 |
C-EGF18 | >100 | >100 | >100 | 4.85 |
C-EGF19 | 12.1 | >100 | >100 | 95.7 |
C-EGF20 | - | - | - | - |
C-EGF21 | 22.5 | 11.9 | >100 | >100 |
C-EGF22 | 1.07 | 0.495 | 24.9 | >100 |
C-EGF23 | 3.86 | 0.616 | 28.2 | >100 |
C-EGF24 | 0.129 | 0.0002 | 24.7 | >100 |
C-EGF25 | 0.501 | 0.198 | 1.23 | 54.6 |
C-EGF26 | 0.146 | 0.007 | 52.6 | >100 |
x001 | 0.115 | 0.029 | 3.97 | >100 |
X002 | 0.420 | 0.154 | 8.03 | >100 |
X003 | 0.179 | 0.125 | 3.44 | >100 |
X004 | 0.261 | 0.181 | >100 | >100 |
X005 | 0.333 | 0.023 | 16.2 | >100 |
X006 | 0.543 | 0.108 | 62.5 | >100 |
X007 | 0.696 | 0.256 | 3.48 | >100 |
X008 | 1.10 | 0.179 | 29.9 | >100 |
X009 | 0.710 | 0.003 | >5.0 | >100 |
X010 | 0.173 | 0.053 | 1.45 | 41.5 |
X011 | - | - | - |
Table2
从附图23,24,25,26中可以清晰地看出7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物明显抑制H1975(L858R/T790),HCC827(DEL746-750)两类细胞的增值,而对野生型细胞A431(High level),NCI-H820(WT)在低浓度没有明显抑制,充分说明7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物选择性作用于针对吉非替尼耐药的单点突变或者多点突变的肺癌细胞,具有很大的临床用药意义。
实施例35
7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物对H1975细胞凋亡及细胞周期的影响
Annexin V检测化合物对细胞凋亡的影响:8x105个/孔,NCI-H820,A431,HCC827,EGFRE746-A750deletion),H1975种六孔板。24h后,使用不同浓度化合物及对照(1‰DMSO)处理24h,48h。用胰酶将细胞消化后收集并收集培养基中的细胞,500g离心10min。PBS重悬并500g离心10min,重复2次,binding buffer重悬,5×105-1×106个/ml。PE-Annexin V(556421,BD Pharmingen)各5ul,室温避光15min,流式检测(FACS Calibur,BD)。
PI检测化合物对细胞周期的影响:8x105个/孔,NCI-H820,A431,HCC827,EGFR E746-A750deletion),H1975种六孔板。24h后,使用不同浓度化合物及对照(1‰DMSO)处理24h,48h。用胰酶将细胞消化后收集细胞,500g离心10min。PBS重悬并500g离心10min,重复2次,先加入300ul预冷的PBS,混匀后再加入-20度预冷的无水乙醇700ul,混匀,-20度固定24h以上。5000rpm离心2min。PBS洗2遍。200ulPBS重悬(需要保证细胞浓度在10-6左右),加入RNase至终浓度50ug/ml,37度消化30min。加入PI至终浓度10ug/ml,避光染色30min。1h内上机检测。
化合物C-EGF06能显著引起细胞周期的阻滞,并能引起细胞凋亡。见附图27,28,29。
实施例36
7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物对H1975细胞信号通路的的影响使用常规Western Blot(免疫印迹法),其包括四个步骤:样品制备;电泳分离;蛋白的膜转移;免疫杂交与显色——蛋白检测。
样品制备
1.培养细胞或药物处理。
2.弃培养基,用1X PBS漂洗细胞2次,去尽残留培养基。
3.加入1X SDS样品缓冲液(6-well plate,100μl/w或75cm2 plate,500-1000μl/瓶),刮落细胞,转移到Ep管。
4.超产10~15秒剪切DNA以减低样品粘性。
5.煮沸样品5minutes。
6.离心12000g,5min,取上清。
电泳分离:上样15μl~20μl至SDS-PAGE胶(10cmx10cm)电泳。
电泳分离(参照SDS-PAGE电泳方法)
转膜
1.将胶浸于转移缓冲液中平衡10min。
2.依据胶的大小剪取膜和滤纸6片,放入转移缓冲液中平衡10min。PVDF膜需用纯甲醇浸泡饱和3-5秒钟。
3.装配转移三明治:海绵→3层滤纸→胶→膜→3层滤纸→海绵,每层放好后,用试管赶去气泡。
4.将转移槽置于冰浴中,放入三明治(黑色面对黑色面),加转移缓冲液,插上电极,100V,1h(电流约为0.3A)。转膜结束后,切断电源,取出杂交膜免疫杂交与显色
1.用25ml TBS洗膜5min,室温,摇动。
2.置膜于25ml封闭缓冲液中1h,室温,摇动。
3.15ml TBS/T洗6次(5min/T)。
4.加入合适稀释度的一抗,室温孵育1-2h或4℃过夜。
5.15ml TBS/T洗6次(5min/T)。
6.加入合适稀释度的碱性磷酸酶(AP)或辣根过氧化酶(HRP)标记的二抗,室温孵育1h,缓慢摇动。
7.15ml TBS/T洗3次(5min/T)。
8.15ml TBS洗1次。
9.用ECL进行蛋白压片。
10.显影。
化合物C-EGF06能显著引起EGFR磷酸化的阻滞,并进而阻断了下游通路磷酸化。见附图30。
以上是针对本发明的可行实施例的具体说明,但该实施例并非用以限制本发明的专利范围,凡未脱离本发明技艺精神所为的等效实施或变更,均应包含于本发明的专利范围中。
Claims (7)
1.具有式(I)或(II)结构的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物或者其药学上可接受的盐或立体异构体或其前药分子:
其中,Y任选自:CH或N;
R1任选自:
1).H;
2).C1~C5烷基;
3).C3~C6环烷基;
4).C1~C5含氟烷基;
5).(CH2)nX,n=0~6,X为羟基,氨基,C1~C6含杂原子烷基,C3~C7杂环基;A1,A2,A3,A4,A5任选自:卤素,氰基,硝基,羟基,氨基,C1~C6烷基,C3~C6环烷基,C1~C6含氟烷基,C1~C6含杂原子烷基,C1~C7杂环基以及上述烷基形成的酯,酰胺,砜,亚砜,脲;
R2任选自:
1).H;
2).C1~C5烷基;
3).C3~C6环烷基;
4).C1~C5含氟烷基;
5).芳基;
6).杂环基;
R3任选自:
1).H;
2).卤素;
3).氨基,羟基,氰基,硝基;
4).C1~C5烷基;
5).C3~C6环烷基;
6).芳基;
W任选自:CH2,CH2CH2,O,S,NH,NR;R为烷基或芳基;
R4任选自:
1)H;
2)卤素;
3)C1~C5烷基;
4)C3~C6环烷基
5)芳基
以上所述环烷基、芳基可任选被0,1,2或3个任选自R5的取代基取代;
R5任选自:
1)H;
2)卤素;
3)C1~C3烷基;
4)C3~C6环烷基;
5)C1~C3烷氧基;
6)C1~C3含氟烷基;
7)杂环基;
8)C0~C3亚烷基-杂环基;
9)苯基。
2.根据权利要求1所述的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物或者其药学上可接受的盐或其前药分子,其具有式III结构:
R3如权利要求1所述;
所述R1选自:
1)H;
2)甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;正戊基,异戊基,新戊基;
3)环丙基,环丁基,环戊基,环己基;
4)(CH2)nX,n=0~6,X为羟基,氨基,甲氧基,乙氧基,甲氧基乙氧基,乙氧基乙氧基相关含氧烷基,甲巯基,N,N-二甲基,N-甲基哌嗪基,吗啡啉基,硫啡啉基,哌啶基,四氢吡咯基,4-N,N-二甲基哌啶基,1-甲基-4-(哌嗪-4-取代)哌啶基,咪唑基,6-(4-甲基哌嗪-1-取代)-3-取代吡啶基相关杂环;
A1,A2,A3,A4,A5任选自:H,氟,氯,溴,碘,甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;正戊基,异戊基,新戊基相关支链烷烃,甲氧基,乙氧基,异丙氧基,叔丁氧基,甲氧基乙氧基,乙氧基乙氧基相关含氧烷烃,三氟甲基相关含氟烷烃,N,N-二甲基氨基乙氧基,N,N-二甲基氨基丙氧基,2-(N-甲基哌嗪基)乙氧基,2-(N-乙酰基哌嗪基)乙氧基,2-吗啡啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,2-四氢吡咯基乙氧基相关杂环烷氧基,N-甲基哌嗪基,吗啡啉基,硫啡啉,哌啶,四氢吡咯,咪唑,3-N,N-二甲基四氢吡咯,4-N,N-二甲基哌啶,4-乙酰基哌嗪,1-甲基-4-(哌嗪-4-取代)哌啶,4-(4-甲基哌嗪-1-取代)甲基,1-甲基哌啶-4-氨基,4-哌嗪-2-酮,1-甲基-4-哌嗪-2-酮相关杂环,以及上述基团形成的酯,酰胺,砜,亚砜,脲;
所述R2选自:
1)H;
2)甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;正戊基,异戊基,新戊基;
3)环丙基,环丁基,环戊基,环己基;
4)苯基,苄基,对甲氧基苯基,联苯基,4-苯氧基苯基,4-苄氧基苯基,2,4二氯苯基,3-氯-4-氟苯基单取代或多取代苯基,1-奈基,2-萘基。
3.根据权利要求2所述的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物或者其药学上可接受的盐或其前药分子,其具有式IV结构:
R1、R2如权利要求2所述;
所述R6,R7任选自:
1)H;
2)甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;正戊基,异戊基,新戊基;
3)环丙基,环丁基,环戊基,环己基;
4)苯基;
W任选自:CH2,CH2CH2,O,S,NH,NR;R为甲基,乙基,苯基;
R4优先选自:
1)H;
2)氟,氯,溴,碘;
3)甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基;
4)环丙基,环丁基,环戊基,环己基;
5)苯基,单取代或多取代苯基,稠环以及含杂原子稠环。
4.根据权利要求1-3任一所述的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物或者其药学上可接受的盐或立体异构体或其前药分子,其特征是,所述化合物选自:
N-(3-(3-甲基-7-(甲氨基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-甲基-2-氧-7-(苯胺基)-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-甲基-7-(4-甲基哌嗪-1-取代)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-(哌啶-1-取代)苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-(吡咯-1-取代)苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-吗啡啉苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-硫啡啉苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-(4-(4-甲基哌嗪-1-取代)哌啶-1-取代)苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(4-(4-(二甲氨基)哌啶-1-取代)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-(4-甲基-1,4-二氮杂环庚烷-1-取代)苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
(R)-N-(3-(7-(4-(3-(二甲氨基)吡咯-1-取代)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
(S)-N-(3-(7-(4-(3-(二甲氨基)吡咯-1-取代)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(4-(4-乙酰基哌嗪-1-取代)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(4-(二甲氨基)-2-甲氧基苯胺)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-氟-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-(2-甲氧基乙氧基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-异丙基-7-(2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-(4-甲氧基苯)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-环丙基-7-(2-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-甲基-7-(4-(4-4-甲基哌嗪-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-甲基-2-氧-7-(4-(哌啶-1-取代)苯胺基)-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-甲基-7-(4-(4-(4-甲基哌嗪-1-取代)哌啶-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(4-(4-(二甲氨基)哌啶-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-甲基-2-氧-7-(4-硫啡啉苯胺基)-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-异丙氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-甲基-7-(4-吗啡啉苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-甲氧基-4-(2-吗啡啉乙氧基)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(2-乙氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(3-甲基-7-(2-甲基-4-(4-甲基哌嗪-1-取代)苯胺基)-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺;
N-(3-(7-(3-甲氧基-4-(4-甲基哌嗪-1-取代)苯胺基)-3-甲基-2-氧-3,4-二氢嘧啶[4,5-d]嘧啶-1(2氢)-取代)苯基)丙烯酰胺。
5.一种治疗肿瘤的药用组合物,其药学活性成份为权利要求1-4任一项所述的7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物或其药学上可接受的盐或立体异构体或其前药分子。
6.权利要求1-4任一项所述7-(取代氨基)-3,4-二氢嘧啶[4,5-d]吡啶-(1氢)-酮类化合物及其药学上可接受的盐或立体异构体或其前药分子在制备治疗肿瘤的药物中的应用。
7.根据权利要求6所述的应用,其特征是:所述肿瘤为非小细胞肺癌、小细胞肺癌、肺腺癌、肺鳞癌、胰腺癌、乳腺癌、前列腺癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌、鼻咽癌中的任一种。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110156399.9A CN102816162B (zh) | 2011-06-10 | 2011-06-10 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
US14/125,304 US20140296216A1 (en) | 2011-06-10 | 2011-12-21 | Pyrimido[4,5-d]pyrimidinyl compounds, pharmaceutical compositions and uses thereof |
PCT/CN2011/002152 WO2012167415A1 (zh) | 2011-06-10 | 2011-12-21 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
CA2838885A CA2838885A1 (en) | 2011-06-10 | 2011-12-21 | Pyrimido[4,5-d]pyrimidinyl compounds, pharmaceutical compositions and use thereof |
EP11867338.3A EP2746283A4 (en) | 2011-06-10 | 2011-12-21 | PYRIMIDOPYRIMIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES |
AU2011370586A AU2011370586A1 (en) | 2011-06-10 | 2011-12-21 | Pyrimidopyrimidone derivatives, pharmaceutical compositions and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110156399.9A CN102816162B (zh) | 2011-06-10 | 2011-06-10 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102816162A true CN102816162A (zh) | 2012-12-12 |
CN102816162B CN102816162B (zh) | 2016-04-27 |
Family
ID=47295329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110156399.9A Active CN102816162B (zh) | 2011-06-10 | 2011-06-10 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20140296216A1 (zh) |
EP (1) | EP2746283A4 (zh) |
CN (1) | CN102816162B (zh) |
AU (1) | AU2011370586A1 (zh) |
CA (1) | CA2838885A1 (zh) |
WO (1) | WO2012167415A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014089913A1 (zh) * | 2012-12-12 | 2014-06-19 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的并环化合物 |
US20160176825A1 (en) * | 2013-07-09 | 2016-06-23 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
WO2016124160A1 (zh) * | 2015-02-06 | 2016-08-11 | 华东理工大学 | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 |
WO2017144025A1 (zh) * | 2016-02-26 | 2017-08-31 | 华东理工大学 | 作为EGFR抑制剂的嘧啶并[4,5-d][1,3]噁嗪-2-酮衍生物及其应用 |
CN113801139A (zh) * | 2020-06-12 | 2021-12-17 | 华东理工大学 | 作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
US9346801B2 (en) | 2013-03-01 | 2016-05-24 | Amgen Inc. | Substituted 7-oxo-pyrido[2,3-d]pyrimidines and methods of use |
AU2014223396A1 (en) * | 2013-03-01 | 2015-08-27 | Amgen Inc. | Substituted 7-oxo-pyrido [2, 3-d] pyrimidines and methods of use |
EP3036231B1 (en) | 2013-08-22 | 2020-02-26 | Jubilant Biosys Ltd. | Substituted pyrimidine compounds, compositions and medicinal applications thereof |
ES2679521T3 (es) | 2013-10-18 | 2018-08-28 | Eisai R&D Management Co., Ltd. | Inhibidores pirimidínicos de FGFR4 |
EP3172213B1 (en) | 2014-07-21 | 2021-09-22 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
CA2954186A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
WO2016023014A2 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
ES2864712T3 (es) | 2015-04-14 | 2021-10-14 | Eisai R&D Man Co Ltd | Compuesto inhibidor de FGFR4 cristalino y usos del mismo |
CN106279173A (zh) * | 2015-05-29 | 2017-01-04 | 华东理工大学 | 蝶啶酮衍生物作为egfr抑制剂的应用 |
EP3454898B1 (en) | 2016-05-10 | 2021-11-10 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
EP4047001A3 (en) * | 2016-07-05 | 2022-11-30 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
BR112019017741A2 (pt) | 2017-02-28 | 2020-04-07 | Dana Farber Cancer Inst Inc | usos de pirimidopirimidinonas como inibidores de sik |
CN109836427B (zh) * | 2017-11-29 | 2022-04-15 | 暨南大学 | 嘧啶并嘧啶酮类化合物及其应用 |
KR102377007B1 (ko) * | 2018-09-20 | 2022-03-22 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체 |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220229072A1 (en) | 2019-06-04 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
KR102329720B1 (ko) * | 2019-08-30 | 2021-11-23 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체 |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
KR102382613B1 (ko) * | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4886807A (en) * | 1984-04-24 | 1989-12-12 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel pyrimidopyrimidine derivative, process for producing it and pharmaceutical composition |
US6451804B1 (en) * | 1999-10-21 | 2002-09-17 | Syntex (U.S.A.) Llc | Heteroalkylamino-substituted bicyclic nitrogen heterocycles |
CN1675214A (zh) * | 2002-08-14 | 2005-09-28 | 霍夫曼-拉罗奇有限公司 | 具有抗增殖活性的嘧啶并化合物 |
US20090099190A1 (en) * | 2006-09-14 | 2009-04-16 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2228123T3 (es) * | 1998-10-23 | 2005-04-01 | F. Hoffmann-La Roche Ag | Heterociclos de nitrogeno biciclicos. |
AR030053A1 (es) * | 2000-03-02 | 2003-08-13 | Smithkline Beecham Corp | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas |
-
2011
- 2011-06-10 CN CN201110156399.9A patent/CN102816162B/zh active Active
- 2011-12-21 EP EP11867338.3A patent/EP2746283A4/en not_active Withdrawn
- 2011-12-21 CA CA2838885A patent/CA2838885A1/en not_active Abandoned
- 2011-12-21 US US14/125,304 patent/US20140296216A1/en not_active Abandoned
- 2011-12-21 AU AU2011370586A patent/AU2011370586A1/en not_active Abandoned
- 2011-12-21 WO PCT/CN2011/002152 patent/WO2012167415A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4886807A (en) * | 1984-04-24 | 1989-12-12 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel pyrimidopyrimidine derivative, process for producing it and pharmaceutical composition |
US6451804B1 (en) * | 1999-10-21 | 2002-09-17 | Syntex (U.S.A.) Llc | Heteroalkylamino-substituted bicyclic nitrogen heterocycles |
CN1675214A (zh) * | 2002-08-14 | 2005-09-28 | 霍夫曼-拉罗奇有限公司 | 具有抗增殖活性的嘧啶并化合物 |
US20090099190A1 (en) * | 2006-09-14 | 2009-04-16 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
Non-Patent Citations (1)
Title |
---|
KOSAKU HIROTA ET AL.: "Novel ring transformations of 5-cyanouracils into 2-thiocytosines, 2,4-diaminopyrimidines,and pyrimido[4,5-d]pyrimidines by the reaction with thioureas and guanidines", 《JOURNAL OF THE CHEMICAL SOCIETY,PERLIN TRANSACTIONS 1》, no. 1, 31 December 1990 (1990-12-31), pages 125 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104968664A (zh) * | 2012-12-12 | 2015-10-07 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的并环化合物 |
WO2014089913A1 (zh) * | 2012-12-12 | 2014-06-19 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的并环化合物 |
US9783504B2 (en) * | 2013-07-09 | 2017-10-10 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
US20160176825A1 (en) * | 2013-07-09 | 2016-06-23 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
US10906878B2 (en) | 2013-07-09 | 2021-02-02 | Dana Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
US10316002B2 (en) | 2013-07-09 | 2019-06-11 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
CN105985342B (zh) * | 2015-02-06 | 2018-07-24 | 华东理工大学 | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 |
CN107428763A (zh) * | 2015-02-06 | 2017-12-01 | 华东理工大学 | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 |
CN105985342A (zh) * | 2015-02-06 | 2016-10-05 | 华东理工大学 | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 |
WO2016124160A1 (zh) * | 2015-02-06 | 2016-08-11 | 华东理工大学 | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 |
CN107129506A (zh) * | 2016-02-26 | 2017-09-05 | 华东理工大学 | 作为EGFR抑制剂的嘧啶并[4,5-d][1,3]噁嗪-2-酮衍生物及其应用 |
WO2017144025A1 (zh) * | 2016-02-26 | 2017-08-31 | 华东理工大学 | 作为EGFR抑制剂的嘧啶并[4,5-d][1,3]噁嗪-2-酮衍生物及其应用 |
CN107129506B (zh) * | 2016-02-26 | 2019-10-22 | 华东理工大学 | 作为EGFR抑制剂的嘧啶并[4,5-d][1,3]噁嗪-2-酮衍生物及其应用 |
CN113801139A (zh) * | 2020-06-12 | 2021-12-17 | 华东理工大学 | 作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20140296216A1 (en) | 2014-10-02 |
EP2746283A1 (en) | 2014-06-25 |
EP2746283A4 (en) | 2014-11-05 |
AU2011370586A1 (en) | 2014-01-16 |
CA2838885A1 (en) | 2012-12-13 |
CN102816162B (zh) | 2016-04-27 |
WO2012167415A1 (zh) | 2012-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102816162B (zh) | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 | |
ES2873515T3 (es) | Derivado de quinolona, sal o estereoisómero del mismo farmacéuticamente aceptable, como inhibidor de AXL | |
JP5756518B2 (ja) | 複素環アルキニルベンゼン化合物と、その医療用組成物および使用 | |
JP2022522778A (ja) | 二環式ヘテロシクリル化合物及びその使用 | |
EP3225619B1 (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
CN103012399B (zh) | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 | |
CN104418860B (zh) | 嘧啶并杂环类化合物及其药用组合物和应用 | |
CN103374000B (zh) | 嘧啶并二氮杂卓类化合物及其药用组合物和应用 | |
KR102245280B1 (ko) | 중수소화 3-(4,5-치환 아미노피리미딘) 페닐 유도체 및 그의 응용 | |
ES2936263T3 (es) | Compuesto de quinolina o quinazolina y su aplicación | |
ES2871140T3 (es) | Derivados bicíclicos de piridina, pirazina y pirimidina como inhibidores de PI3K beta | |
CN103570731B (zh) | 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用 | |
CN114539263A (zh) | 一类含氮并杂环化合物及其药用组合物和应用 | |
WO2021180008A1 (zh) | 含脲结构的三芳环化合物及其应用 | |
CN112313213A (zh) | 3-氨基吡唑类化合物及其应用 | |
CA3025594C (en) | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190131 Address after: 523000 Huihai Building, 430 Dongguan Avenue, Yuanwubian Community, Nancheng Street, Dongguan City, Guangdong Province Patentee after: Dongguan Guangdong, Hong Kong and Macao Stem Cell Biotechnology Co., Ltd. Address before: 510663 190 Kaiyuan Avenue, Guangzhou Science City, Guangzhou, Guangdong Province Patentee before: Guangzhou Biomedicine and Health Inst., Chinese Academy of Sciences |